var title_f32_60_33728="Burkitt lymphoma endosc";
var content_f32_60_33728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Burkitt lymphoma on endoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lobulated, ulcerated protuberances seen on retroflexed view during endoscopy in a patient with abdominal pain. Biopsy revealed them to be Burkitt lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33728=[""].join("\n");
var outline_f32_60_33728=null;
var title_f32_60_33729="Sunburn prevention";
var content_f32_60_33729=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sunburn prevention (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/60/33729/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/60/33729/contributors\" id=\"au7188\">",
"       Sylvia Brice, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/60/33729/contributors\" id=\"au7184\">",
"       Kathryn R Shrift, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/60/33729/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/60/33729/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/60/33729/contributors\" id=\"se3610\">",
"       Craig A Elmets, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/60/33729/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/60/33729/contributors\" id=\"de7805\">",
"       Rosamaria Corona, MD, DSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/60/33729?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of effective ways to prevent sunburn, including staying out of the sun during peak hours, sunscreen, and protective clothing. While these measures are important for everyone, they are especially important for children and people with fair skin.",
"    </p>",
"    <p>",
"     This article discusses ways to prevent sunburn. The treatment of sunburn is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/30/18913?source=see_link\">",
"      \"Patient information: Sunburn (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about sunburn is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=see_link\">",
"      \"Sunburn\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      AVOID SUN EXPOSURE",
"     </span>",
"    </p>",
"    <p>",
"     It is important to prepare for sun exposure, especially if you plan to be out in the sun for an extended period of time or during the middle of the day, when the sun's rays are strongest (10:00 AM to 4:00 PM during daylight savings time in the continental United States).",
"    </p>",
"    <p>",
"     Even on cloudy days, it is important to protect your skin because UV radiation can pass through the clouds and cause sunburn. In addition, UV rays can be reflected off of surfaces like sand, snow, cement, and water. Using two types of protection",
"     <span class=\"nowrap\">",
"      (shade/clothing",
"     </span>",
"     plus sunscreen) is the best way to reduce sun exposure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Seek shade",
"     </span>",
"     &nbsp;&mdash;&nbsp;Areas that are shaded receive less UV radiation, and can reduce your chances of developing a sunburn. Trees, an umbrella, or a structure (eg, porch, tent) can help to provide shade. Sunscreen is still recommended while sitting in the shade because your skin is exposed to some UV rays, even in the shade.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      UV index",
"     </span>",
"     &nbsp;&mdash;&nbsp;The UV index was developed to predict the risk of sunburn in your area on a given day based upon the weather conditions. It gives a number between zero and 11+, in which zero indicates a low risk of sun exposure; 10 indicates a very high risk of exposure; and 11+ is an extreme risk of sun exposure. You can find information about the UV index online at",
"     <a class=\"external\" href=\"file://www.epa.gov/sunwise/uvindex.html\">",
"      www.epa.gov/sunwise/uvindex.html",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SUNSCREEN",
"     </span>",
"    </p>",
"    <p>",
"     There are a wide variety of sun-blocking agents (sunscreens) available to protect your skin from sunburn, including gels, lotions, and sprays. Sunscreen protects the skin by absorbing or reflecting UV radiation. The Sun Protection Factor (SPF) is an indicator of how much protection the sunscreen offers against UVB (sunburn) rays. You should look for a sunscreen that is labeled as broad-spectrum, meaning it protects against both UVA and UVB rays.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      What SPF is best?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most healthcare providers, as well as the American Academy of Dermatology, recommend the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Use a sunscreen with an SPF of 30 or greater on exposed skin",
"      </li>",
"      <li>",
"       Use a sunscreen that protects against both UVA and UVB radiation.",
"      </li>",
"      <li>",
"       You may need a higher SPF if you are fair-skinned, if you will be in the sun for a long time, or if you anticipate intense sun exposure (eg, while at the beach or skiing).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      How much sunscreen do I need?",
"     </span>",
"     &nbsp;&mdash;&nbsp;You should apply sunscreen generously to all exposed skin 15 to 30 minutes before exposure. Exposed skin is any skin that is not protected from the sun.",
"    </p>",
"    <p>",
"     You need approximately 1 ounce (2 tablespoons) of lotion to cover an adult's arms, legs, neck, and face. You may need more sunscreen to cover your chest and back. Applying less than this amount may reduce the sunscreen's SPF rating.",
"    </p>",
"    <p>",
"     You should reapply sunscreen after sweating, rubbing the skin, drying off with a towel, or swimming. The traditional advice is to reapply sunscreen every two to three hours. However, some evidence suggests that reapplying sunscreen as soon as 20 minutes after going outside may offer greater protection, allowing you to completely cover areas that you might have missed when you first applied sunscreen. You should then re-apply every two to three hours.",
"    </p>",
"    <p>",
"     Protect your lips with lip balm containing a SPF of 30 or higher and re-apply frequently. Some cosmetic products (eg, liquid foundation, lipstick) and moisturizers contain sun-protective ingredients, although to be truly effective, these products should be labeled as having an SPF of 15 or higher. However, many of these products provide little or no UVA protection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27823210\">",
"     <span class=\"h2\">",
"      Sunscreen and vitamin D",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although ultraviolet light has a number of deleterious consequences, wavelengths within the UVB spectrum have the beneficial effect of increasing the production of vitamin D by the skin. Some studies have shown that sunscreens reduce vitamin D levels, but the amount of sunscreen that most people apply produces only a modest reduction in vitamin D levels. For those individuals who are not vitamin D deficient or at risk for vitamin D deficiency, no reduction in sunscreen use is necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Does sunscreen expire?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemical sunscreens may become less effective over time, and leaving them in high temperatures (eg, car, beach) may speed the process. Manufacturers and others recommend throwing away sunscreen when it has passed the expiration date listed on the bottle. For sunscreen that does not have an expiration date, a typical recommendation is to throw it away after three years. Expired sunscreen may be less effective, potentially reducing the SPF rating and increasing your risk of sunburn.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Clothing",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to sunscreen, consider covering exposed skin with a wide-brimmed hat, long-sleeved shirt, and long pants. A hat made of tightly-woven material (eg, canvas) can provide shade for the face, ears, and back of the neck. Sunglasses that provide 100 percent UV ray protection can reduce your risk of cataracts (clouding in the eye's lens); wraparound glasses provide the most complete protection.",
"    </p>",
"    <p>",
"     Clothing made from tightly-woven dark fabrics tends to provide greater protection than light-colored fabrics. Some manufacturers have sun-protective clothing with SPF. In addition, UV absorbing agents can be applied to clothing in the laundry.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Tips for children",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children are at higher risk than adults for becoming sunburned for several reasons. Children are usually unaware of the risks of sunburn and are less likely to use preventive measures (eg, sunscreen, shade).",
"    </p>",
"    <p>",
"     The safety of sunscreen has not been tested in infants younger than six months, and sunscreens are not usually recommended for this age group. Instead, parents are encouraged to use hats, sunglasses, and shade to protect children from the sun. However, you may apply a minimal amount of sunscreen with an SPF of 15 or higher to small areas in young infants (eg, face, back of hands) when adequate clothing and shade are not available. Sensitive skin or \"baby\" formulas are recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      SUN TANNING",
"     </span>",
"    </p>",
"    <p>",
"     Tanning increases your skin's production of melanin, which provides some minimal protection to the skin against further damage from UV radiation. However, the small benefit of tanning (protection from sunburn) does not outweigh the risks (skin cancer, aged skin).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Outdoor tanning",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your skin tans after being in the sun, gradual sun exposure that allows tanning appears to decrease the risk of sunburn. However, tanning also increases the long-term consequences of sun exposure, such as skin cancer and wrinkling. Thus, gradual tanning in the sun is not the best method for preventing sunburn.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Tanning beds",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most tanning beds emit ultraviolet radiation in the UVA range. Although both UVA and UVB can cause tanning, only UVB-induced tans provide protection against further UV-induced damage to your DNA. Therefore there is little, if any, protection from tanning beds against further UV damage from the sun. Moreover, tanning beds can cause sunburn and have been linked to an increased risk of melanoma, a potentially deadly form of skin cancer. Most experts do not recommend using tanning beds, especially for those under age 18 years. For those who do use tanning beds, it is particularly important to use protective eyewear when the sunlamp is on because tanning beds can cause cataracts and melanoma of the eye.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Sunless tanning",
"     </span>",
"     &nbsp;&mdash;&nbsp;As people become more aware of the risks of skin cancer from sun exposure and tanning beds, sunless tanning products have become increasingly popular. A variety of safe and natural-appearing sunless tanning products are available, including lotions, gels, and sprays.",
"    </p>",
"    <p>",
"     These products stain the skin, making it darker. The staining is temporary, usually lasting less than one week unless you reapply the product. While sunless tanning products are generally safe, the \"tan\" you get does not protect against sunburn.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Other tanning products",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tanning accelerators and tanning pills are advertised to darken the skin, either in combination with sun exposure or by coloring the skin directly. However, these products have not been tested and it is not clear if they are safe; the sale of tanning pills has been banned in the United States.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164454\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164461\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/46/42722?source=see_link\">",
"      Patient information: Melanoma skin cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/26/26018?source=see_link\">",
"      Patient information: Skin cancer (non-melanoma) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/20/23874?source=see_link\">",
"      Patient information: Sunburn (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/8/19586?source=see_link\">",
"      Patient information: Actinic keratosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/39/9842?source=see_link\">",
"      Patient information: Keloids (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/41/37521?source=see_link\">",
"      Patient information: Melasma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164505\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/30/18913?source=see_link\">",
"      Patient information: Sunburn (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32164522\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=see_link\">",
"      Primary prevention of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=see_link\">",
"      Sunburn",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21193?source=see_link\">",
"      Vitiligo",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Dermatology",
"       <br/>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.aad.org/media-resources/stats-and-facts/prevention-and-care/sunscreens/sunscreens\">",
"      www.aad.org/media-resources/stats-and-facts/prevention-and-care/sunscreens/sunscreens",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/sunexposure.html\">",
"      www.nlm.nih.gov/medlineplus/sunexposure.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cdc.gov/cancer/skin/chooseyourcover/\">",
"      www.cdc.gov/cancer/skin/chooseyourcover/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/cancertopics/pdq/prevention/skin/Patient/page2\">",
"      www.nci.nih.gov/cancertopics/pdq/prevention/skin/Patient/page2",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Environmental Protection Agency",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.epa.gov/sunwise/\">",
"      www.epa.gov/sunwise/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Skin Cancer Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.skincancer.org/index.php\">",
"      www.skincancer.org/index.php",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Council on Skin Cancer Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.skincancerprevention.org\">",
"      www.skincancerprevention.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?32/60/33729/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/60/33729?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33729/abstract/1\">",
"      Moloney FJ, Collins S, Murphy GM. Sunscreens: safety, efficacy and appropriate use. Am J Clin Dermatol 2002; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33729/abstract/2\">",
"      Faurschou A, Wulf HC. The relation between sun protection factor and amount of suncreen applied in vivo. Br J Dermatol 2007; 156:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33729/abstract/3\">",
"      Stumpf, JL. Myths and facts about sunscreen shelf life and SPF. US Pharm 2004; 8:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33729/abstract/4\">",
"      Sambandan DR, Ratner D. Sunscreens: an overview and update. J Am Acad Dermatol 2011; 64:748.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f32_60_33729=[""].join("\n");
var outline_f32_60_33729=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           AVOID SUN EXPOSURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SUNSCREEN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           SUN TANNING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f32_60_33730="Tympanostomy tube placement";
var content_f32_60_33730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tympanostomy tube placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    1) Otitis media with effusion, 2) anterior incision of the drum, 3) aspiration of effusion, 4) tube inserted with cuff forceps, 5) completed tube placement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesty of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33730=[""].join("\n");
var outline_f32_60_33730=null;
var title_f32_60_33731="Physostigmine: Patient drug information";
var content_f32_60_33731=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Physostigmine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     see \"Physostigmine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=see_link\">",
"     see \"Physostigmine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10193438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2745752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some overdoses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10193437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2745748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to physostigmine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2745749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, high blood sugar (diabetes), heart disease, bowel block, or trouble passing urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10193441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10193465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10193443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10193440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10193466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10193464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15558 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33731=[""].join("\n");
var outline_f32_60_33731=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10193438\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10193437\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10193441\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10193465\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10193443\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10193440\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10193466\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10193464\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=related_link\">",
"      Physostigmine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=related_link\">",
"      Physostigmine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_60_33732="Silodosin: Patient drug information";
var content_f32_60_33732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Silodosin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/15/17653?source=see_link\">",
"     see \"Silodosin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6813986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rapaflo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13737687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rapaflo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In men, it is used to treat the signs of an enlarged prostate.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not approved for use in women.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to silodosin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad kidney or liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having cataract surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a rectal exam (to check prostate gland) and blood work (PSA test). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12203 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33732=[""].join("\n");
var outline_f32_60_33732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6813986\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017748\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017750\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017749\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017754\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017755\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017757\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017752\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017753\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017758\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017759\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/15/17653?source=related_link\">",
"      Silodosin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_60_33733="Vitamin B6 (pyridoxine): Pediatric drug information";
var content_f32_60_33733=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin B6 (pyridoxine): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39254?source=see_link\">",
"    see \"Vitamin B6 (pyridoxine): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/38/33380?source=see_link\">",
"    see \"Vitamin B6 (pyridoxine): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aminoxin&reg; [OTC];",
"     </li>",
"     <li>",
"      Pyri-500 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Cycloserine Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Hydrazine Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Mushroom Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Drug-induced Neuritis, Treatment Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Water Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adequate intake (AI): Oral: 0.1 mg/day (0.01 mg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pyridoxine-dependent seizures: Oral, I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: I.V. preferred: 50-100 mg (Rajesh, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: Oral preferred: Usual: 50-100 mg/day; range: 10-200 mg (Rajesh, 2003); an observational study in UK described a usual dose of 30 mg/kg/day (Baxter, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39254?source=see_link\">",
"      see \"Vitamin B6 (pyridoxine): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adequate intake (AI): Oral: Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 to &lt;6 months: 0.1 mg (0.01 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 months: 0.3 mg (0.03 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recommended daily allowance: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 0.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-19 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Male: 1.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Female: 1.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-50 years: 1.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;50 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Male: 1.7 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Female: 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dietary deficiency: Oral, I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 5-25 mg/day for 3 weeks, then 1.5-2.5 mg/day in multivitamin product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults: 10-20 mg/day for 3 weeks, then 2-5 mg/day (usual dosage  found in multivitamin products)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pyridoxine-dependent seizures: Oral, I.M., I.V.: Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: I.V. preferred: 50-100 mg (Rajesh, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: Oral preferred: Usual: 50-100 mg/day; range: 10-200 mg (Rajesh, 2003); an observational study in UK described a usual dose of 30 mg/kg/day (Baxter, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Drug-induced neuritis (eg, isoniazid, hydralazine, penicillamine, cycloserine): Oral, I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 10-50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 1-2 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cycloserine: Treatment 100-300 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Isoniazid: Treatment: 100 mg/day for 3 weeks; prophylaxis: 30 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Penicillamine: 100-200 mg/day for 3 weeks; prophylaxis: 25-100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of isoniazid-induced seizures and/or coma following acute ingestion: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute ingestion of known amount: Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 70 mg/kg up to 5 g); administer at a rate of 0.5-1 g/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5-10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4-6 hours (Howland, 2006; Morrow, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute ingestion of unknown amount: Initial: 70 mg/kg (maximum dose: 5 g); administer at a rate of 0.5-1 g/minute; may repeat every 5-10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland, 2006; Morrow, 2006; Santucci, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute ingestion of known amount: Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 5 g); administer at a rate of 0.5-1 g/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5-10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4-6 hours (Howland, 2006; Morrow, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute ingestion of unknown amount: Initial: 5 g; administer at a rate of 0.5-1 g/minute; may repeat every 5-10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland, 2006; Morrow, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of isoniazid-induced seizures and/or coma following acute ingestion: I.V.: Children and Adults: Asymptomatic patients who present within 2 hours of ingesting a potentially toxic amount of isoniazid should receive a prophylactic dose of pyridoxine (Boyer, 2006). Dosing recommendations are the same as for the treatment of symptomatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute intoxication: Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrazine ingestion: 25 mg/kg:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     dose I.M. and",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     dose I.V. infusion over 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mushroom ingestion (genus",
"     <i>",
"      Gyromitra",
"     </i>",
"     ): I.V.: 25 mg/kg/dose; repeat as necessary to a maximum total dose of 15-20 g",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 50 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aminoxin&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 100 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride: 200 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 25 mg, 50 mg, 100 mg, 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pyri-500: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: May be administered I.M. or  slow I.V.; seizures have been precipitated following large I.V. doses. pH: 2-3.8",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isoniazid toxicity: Initial doses should be administered at a rate of 0.5-1 g/minute. If the parenteral formulation is not available, anecdotal reports suggest that pyridoxine tablets may be crushed and made into a slurry and given at the same dose orally or via nasogastric (NG) tube (Boyer, 2006) or an extemporaneous compounded solution may be used. Oral administration is not recommended for acutely poisoned patients with seizure activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F216047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in fat emulsion 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10480123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of vitamin B",
"     <sub>",
"      6",
"     </sub>",
"     deficiency; treatment of drug-induced deficiency (eg, isoniazid or oral contraceptives); treatment of inborn errors of metabolism (eg, B",
"     <sub>",
"      6",
"     </sub>",
"     -dependent seizures or anemia); injection may be used when oral route not feasible (FDA approved in adults); has also been used for the treatment of  pyridoxine-dependent seizures in infants; treatment of acute intoxication of isoniazid, cycloserine, hydrazine, and mushroom (genus",
"     <i>",
"      Gyromitra",
"     </i>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pyridoxine may be confused with paroxetine, pralidoxime, Pyridium&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal [Brazil] may be confused with Doxil brand name for DOXOrubicin [U.S.]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal: Brand name for pyridoxine/thiamine combination [Brazil], but also the brand name for doxepin [Finland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F216046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, seizure (following very large I.V. doses), somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, folic acid decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuropathy, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyridoxine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10480122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: Pyridoxine may diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Pyridoxine may increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Pyridoxine may increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Pyridoxine may diminish the therapeutic effect of Levodopa.  Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F215989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Water soluble vitamins cross the placenta. Maternal pyridoxine plasma concentrations may decrease as pregnancy progresses and requirements may be increased in pregnant women (IOM, 1998). Pyridoxine is used to treat nausea and vomiting of pregnancy (Neibyl, 2010). In addition to being a dietary supplement, pyridoxine is also used as an antidote. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administering large I.V. doses, monitor respiratory rate, heart rate, and blood pressure",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For treatment of isoniazid, hydrazine, or gyromitrin-containing mushroom toxicity: Anion gap, arterial blood gases, electrolytes, neurological exam, seizure activity",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1061710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     30-80 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Precursor to pyridoxal and pyridoxamine which function as cofactors in the metabolism of proteins, carbohydrates, and fats; also aids in the release of liver and muscle stored glycogen and in the synthesis of GABA (within the CNS) and heme",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily from the GI tract; primarily in jejunum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted to pyridoxal (active form in liver)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, biologic: 15-20 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: By liver metabolism",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F215984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral solution may be made using pyridoxine injection. Withdraw 100 mg (1 mL of a 100 mg/mL injection) from a vial with a needle and syringe; add to 99 mL simple syrup in an amber bottle. Label \"refrigerate\". Stable for 30 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baxter P, \"Epidemiology of Pyridoxine Dependent and Pyridoxine Responsive Seizures in the UK,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1999, 81(5):431-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33733/abstract-text/10519720/pubmed\" id=\"10519720\" target=\"_blank\">",
"        10519720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW, &ldquo;Antituberculous Medications,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 8th ed, Flomenbaum NE, Goldfrank LR, Hoffman, RS, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2006, 861-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dart RC, Borron SW, Caravati EM, et al,&ldquo;Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2009, 54(3):386-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33733/abstract-text/19406507/pubmed\" id=\"19406507\" target=\"_blank\">",
"        19406507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department Health and Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diaz JH, &ldquo;Syndromic Diagnosis and Management of Confirmed Mushroom Poisonings,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2005, 33(2):427-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33733/abstract-text/15699849/pubmed\" id=\"15699849\" target=\"_blank\">",
"        15699849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Pyridoxine,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 8th ed, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2006, 872-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morrow LE, Wear RE, Schuller D, et al, \"Acute Isoniazid Toxicity and the Need for Adequate Pyridoxine Supplies,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(10):1529-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33733/abstract-text/16999664/pubmed\" id=\"16999664\" target=\"_blank\">",
"        16999664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagappan R and Riddell T, &ldquo;Pyridoxine Therapy in a Patient With Severe Hydrazine Sulfate Toxicity,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2000, 28(6):2116-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33733/abstract-text/10890675/pubmed\" id=\"10890675\" target=\"_blank\">",
"        10890675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rajesh R and Girija AS, \"Pyridoxine-Dependent Seizures: A Review,\"",
"      <i>",
"       Indian Pediatr",
"      </i>",
"      , 2003, 40(7):633-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33733/abstract-text/12881619/pubmed\" id=\"12881619\" target=\"_blank\">",
"        12881619",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Santucci KA, Shah BR, and Linakis JG, \"Acute Isoniazid Exposures and Antidote Availability,\"",
"      <i>",
"       Pediatric Emergency Care",
"      </i>",
"      , 1999, 15(2):99-101.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12753 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33733=[""].join("\n");
var outline_f32_60_33733=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216001\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061707\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444894\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061701\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215977\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215962\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061712\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216047\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480123\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061711\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216049\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216046\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061716\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10480122\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299968\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215971\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215974\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215989\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061706\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061710\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061700\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061715\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215984\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12753|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39254?source=related_link\">",
"      Vitamin B6 (pyridoxine): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/38/33380?source=related_link\">",
"      Vitamin B6 (pyridoxine): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_60_33734="Anhidrotic ectodermal dysplasia";
var content_f32_60_33734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80851%7EDERM%2F66563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80851%7EDERM%2F66563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anhidrotic ectodermal dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sparse hair is evident in this patient with anhidrotic ectodermal dysplasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anhidrotic ectodermal dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conical \"peg\" teeth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33734=[""].join("\n");
var outline_f32_60_33734=null;
var title_f32_60_33735="Echocardiographic evaluation of left ventricular diastolic function";
var content_f32_60_33735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of left ventricular diastolic function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/60/33735/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/60/33735/contributors\">",
"     Sherif F Nagueh, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/60/33735/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/60/33735/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/60/33735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/60/33735/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/60/33735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular (LV) diastolic function can be characterized by invasive and non-invasive methods. Invasive measures of diastolic function include the peak instantaneous rate of LV pressure decline",
"    <span class=\"nowrap\">",
"     (-dP/dt),",
"    </span>",
"    the time constant of LV relaxation (tau), and the stiffness modulus. Although echocardiography does not directly measure these parameters, echocardiography is the most practical routine clinical approach for evaluating LV diastolic function given clinical and experimental evidence supporting its use as well as its safety, versatility, and portability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diastole is conventionally divided into the following phases: isovolumetric relaxation (both aortic and mitral valves are closed and LV pressure is declining), early LV filling with opening of the mitral valve, a mid diastolic phase (often noted in patients with bradycardia), and late or atrial filling with left atrial (LA) contraction. In normal hearts, predominant LV filling occurs in early diastole. With impaired LV relaxation, LV filling shifts to late diastole and becomes dependent on LA systolic function. This accounts for the significant clinical deterioration that is seen in patients with diastolic dysfunction (such as hypertrophic cardiomyopathy) in the presence of atrial fibrillation.",
"   </p>",
"   <p>",
"    The 2007 European Society of Cardiology (ESC) guidelines recognize diastolic dysfunction by echocardiography as one of the criteria for the diagnosis of diastolic heart failure (DHF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic summarizes available echocardiographic methods for assessment of LV diastolic function. Recommendations in this topic are generally in agreement with the American Society of Echocardiography (ASE) recommendations for the evaluation of left ventricular diastolic function by echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis, management and prognosis of diastolic heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATORS OF DIASTOLIC FUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7123086\">",
"    <span class=\"h2\">",
"     Summary of indicators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive assessment of diastolic function begins with evaluation of LV volumes and left ventricular ejection fraction (LVEF), as the algorithms used to draw conclusions about LV diastolic function depend heavily on LVEF.",
"   </p>",
"   <p>",
"    In addition, left ventricular wall thicknesses (to identify presence and extent of left ventricular hypertrophy), left atrial (LA) volumes, and pulmonary artery (PA) pressures should be evaluated since these also help guide assessment of diastolic function. Patients with diastolic heart failure frequently have left ventricular hypertrophy, LA enlargement and increased PA pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"     2",
"    </a>",
"    ]. The peak velocity of the tricuspid regurgitation (TR) jet by continuous wave (CW) Doppler and mean RA pressure (which may be inferred from the inferior vena cava size and its respiratory variation) are used to estimate PA systolic pressure. PA diastolic pressure can be estimated from the pulmonary regurgitation end diastolic velocity and mean RA pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14378?source=see_link\">",
"     \"Echocardiographic evaluation of the tricuspid valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20567?source=see_link\">",
"     \"Echocardiographic evaluation of the pulmonic valve and pulmonary artery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the above, there are specific echocardiographic indicators of diastolic function which include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transmitral Doppler inflow velocity patterns",
"     </li>",
"     <li>",
"      Pulmonary venous Doppler flow patterns",
"     </li>",
"     <li>",
"      Tissue Doppler velocities",
"     </li>",
"     <li>",
"      Color M-mode flow propagation velocity (Vp)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most echocardiographic measurements are highly reproducible with careful adherence to correct acquisition and analysis techniques. Given its wide availability, reproducibility, and versatility, Doppler echocardiography shows promise as a means of guiding HF management, as suggested by a small clinical trial of patients with heart failure with reduced LVEF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Doppler mitral inflow velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmitral Doppler flow is acquired by placing a one to two mm pulsed wave (PW) sample volume at the level of the tips of the mitral leaflets in the apical four-chamber view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75687 \" href=\"mobipreview.htm?41/6/42084\">",
"     image 1",
"    </a>",
"    ). Proper alignment with mitral inflow without angulation is essential, even if foreshortening of the LV results. The normal inflow pattern consists of early (E) and late (A) filling (",
"    <a class=\"graphic graphic_figure graphicRef64146 \" href=\"mobipreview.htm?3/21/3422\">",
"     figure 1",
"    </a>",
"    ). In patients with bradycardia, a pause in flow between early filling and atrial contraction is seen during diastasis. In normal young individuals, predominant forward flow occurs in early diastole largely due to the rapid decline in LV pressure during the isovolumetric relaxation period (IVRT). A continuous wave (CW) recording of the mitral inflow should also be performed to ensure measurement of peak inflow velocities for measurement of mitral inflow gradient.",
"   </p>",
"   <p>",
"    Recording of the IVRT is obtained by placing a CW sample volume midway between LV outflow tract and mitral valve tips in the apical long axis or 5-chamber view [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/4\">",
"     4",
"    </a>",
"    ]. The normally rapid rise and fast decline in E velocity are identified by short acceleration (AT) and deceleration (DT) times. With aging and diastolic dysfunction, more flow occurs with atrial contraction and there is a prolongation in IVRT, AT, and DT.",
"   </p>",
"   <p>",
"    There are three major patterns of abnormal mitral inflow (",
"    <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"mobipreview.htm?31/45/32470\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An impaired relaxation pattern is characterized by a reduced E velocity, an",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio &lt;1, and prolonged IVRT (&gt;90 ms), and DT (&gt;220 ms). Diseases that impair LV relaxation (such as hypertension, coronary artery disease, and cardiomyopathy) in the presence of normal filling pressures can lead to this inflow pattern. Patients with impaired relaxation may be asymptomatic or have reduced exercise tolerance as tachycardia reduces the diastolic filling period leading to a rise in LA pressure and a reduction in LV stroke volume. A pattern of impaired relaxation also is typical in older adults (over age 60 years).",
"     </li>",
"     <li>",
"      A \"pseudonormal\" pattern is present when LA pressure increases in the setting of impaired LV relaxation leading to an inflow pattern in which the",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio is &gt;1 (but less than 2), and the DT and IVRT are shorter than in patients with impaired relaxation LV filling pattern. A pseudonormal pattern may revert to an impaired relaxation pattern when a Valsalva maneuver is performed during echocardiography. In patients with a pseudonormal pattern with associated increased LA pressure, straining leads to a brief reduction in venous return and LA pressure, and the inflow pattern reverts to one with predominant late diastolic filling (ie,",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio &lt;1).",
"     </li>",
"     <li>",
"      Restrictive filling occurs when a further rise in LA pressure leads to an increased",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio (&ge;2) and shortening of the IVRT (&lt;70 ms) and DT (&lt;150 ms). In patients with heart failure as well as in the post-myocardial infarction setting, the presence of a persistent restrictive pattern despite appropriate medical therapy is associated with increased mortality (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65218 \" href=\"mobipreview.htm?31/42/32423\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef63794 \" href=\"mobipreview.htm?39/10/40109\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2,6\">",
"       2,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hemodynamic determinants of mitral inflow velocities and time intervals include LA pressure, LV relaxation, heart rate, ventricular interaction, mitral valve disease, and aortic regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/7\">",
"     7",
"    </a>",
"    ]. Despite the many variables that influence mitral velocities, several studies have indicated that mitral inflow patterns predict outcomes and exercise tolerance in patients with systolic heart failure and may be more predictive than LVEF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=see_link&amp;anchor=H9#H9\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Other echocardiographic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pulmonary venous flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary venous flow can be recorded reliably from the right upper pulmonary vein in most ambulatory patients by transthoracic imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/4\">",
"     4",
"    </a>",
"    ]. The recording is obtained from the apical 4-chamber view with the guidance of color Doppler by placing the sample volume 1 to 2 cm into the vein. Pulmonary venous flow signals can be enhanced by intravenous ultrasound contrast agents. The pulmonary venous flow pattern is characterized by 3 velocities in patients with sinus rhythm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59819 \" href=\"mobipreview.htm?39/1/39956\">",
"     image 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial forward systolic flow (S) is related to left atrial relaxation and left ventricular systolic contraction with mitral annular descent to the apex.",
"     </li>",
"     <li>",
"      During diastole, another phase of forward flow (D) occurs from the veins into the LA. This velocity has hemodynamic determinants that are similar to those of the mitral E velocity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During atrial systole there is retrograde flow from the LA into the pulmonary veins (Ar).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The peak velocity, the duration, and the velocity time integral (TVI) of all 3 waves can be measured. The systolic filling fraction (SFF) is computed as",
"    <span class=\"nowrap\">",
"     S/(S",
"    </span>",
"    + D). It is computed using TVI of the above signals (",
"    <a class=\"graphic graphic_figure graphicRef68801 \" href=\"mobipreview.htm?37/8/38029\">",
"     figure 3",
"    </a>",
"    ), though peak velocities may be used.",
"   </p>",
"   <p>",
"    In healthy young subjects, predominant forward flow occurs in diastole. This decreases with age, and predominant systolic flow is frequently observed in subjects over 60 years old. On the other hand, a prolonged Ar duration indicates elevated late LV diastolic pressures irrespective of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. A SFF &lt;40 percent in patients with depressed EF is a reliable marker of increased LA pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/13\">",
"     13",
"    </a>",
"    ]. Similarly, a short deceleration time of pulmonary venous diastolic velocity has been reported in patients with increased LV filling pressures whether in sinus rhythm or atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limitations to the clinical application of pulmonary venous flow, which include mitral valve disease (which limits use of SFF but not Ar duration), pericardial compression syndromes, heart block, and tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tissue Doppler imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue Doppler imaging (TDI) enables measurement of high amplitude, low frequency Doppler shifts caused by myocardial motion. Segmental and global function can be measured. For global function, the region of interest is placed at the septal and lateral borders of the mitral annulus. During systole, the annulus descends towards the apex, whereas it recoils back toward the base in early (e') and late (a') diastole (",
"    <a class=\"graphic graphic_waveform graphicRef79797 \" href=\"mobipreview.htm?11/62/12262\">",
"     waveform 2",
"    </a>",
"    ). The early diastolic velocity decreases with age and is significantly related to LV relaxation in animal and human studies (",
"    <a class=\"graphic graphic_figure graphicRef53714 \" href=\"mobipreview.htm?16/44/17093\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Importantly, it is minimally affected by preload in patients with impaired LV relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accordingly,",
"    <span class=\"nowrap\">",
"     E/e'",
"    </span>",
"    ratio can be applied for the estimation of LV filling pressures and has been studied in a variety of clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ]. An",
"    <span class=\"nowrap\">",
"     E/e'",
"    </span>",
"    ratio below 8 is associated with normal filling pressures and ratio &gt;12 to 15 is associated with elevated filling pressures.",
"   </p>",
"   <p>",
"    For diagnosis of diastolic heart failure the",
"    <span class=\"nowrap\">",
"     E/e'",
"    </span>",
"    ratio (using the lateral e') has been identified as the best parameter for diagnosis when compared to other Doppler measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. The ratio was clinically useful in patients in tachycardia with merged diastolic velocities and in patients with atrial fibrillation, though additional studies are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Changes in",
"    <span class=\"nowrap\">",
"     E/e'",
"    </span>",
"    ratio and PA pressures with exercise can be used to identify patients with a suspected cardiac etiology for dyspnea (diastolic stress test) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Attention to technical aspects is essential for obtaining high quality signals that can be used for drawing reliable clinical conclusions. In particular, the sample volume must be carefully paced in ventricular myocardium at or within 1 cm of the lateral and septal insertion sites of the mitral leaflets, angulation between the ultrasound beam and the annular plane of motion should be minimized, and gain and filter settings must be optimized for satisfactory signal acquisition.",
"   </p>",
"   <p>",
"    A limitation of TDI is that the",
"    <span class=\"nowrap\">",
"     E/e'",
"    </span>",
"    ratio is not helpful for estimating LV filling pressures in certain populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio does not reliably estimate LV filling pressures in normal subjects and patients with mitral valve disease including heavy mitral annular calcification. In patients with mitral valve disease, some studies have shown that the ratio of IVRT to the time interval between the onset of mitral E and annular e' (T(E-e)) can be used to predict PCWP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with constrictive pericarditis an inverse relationship between",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      and PCWP is observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=see_link&amp;anchor=H13#H13\">",
"       \"Constrictive pericarditis\", section on 'Echocardiography'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Color flow mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Color M-mode provides a spatio-temporal display of the inflow of blood into the LV. Early and late filling signals are observed during diastole (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73870 \" href=\"mobipreview.htm?18/41/19089\">",
"     image 4",
"    </a>",
"    ). In patients with tachycardia, merging between early and late diastolic signals occurs. A single filling velocity is also observed in patients with atrial fibrillation.",
"   </p>",
"   <p>",
"    The flow propagation velocity (Vp) is measured in the apical four-chamber view by placing the M-mode scan line through the center of the column of LV inflow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"     2",
"    </a>",
"    ]. The color flow baseline is shifted to lower the Nyquist limit so that the central highest velocity jet is blue. The Vp is the slope of the first aliasing velocity during early filling measured from the mitral valve plane to 4 cm apically into the left ventricular cavity, or the slope of transition from no color to color (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73870 \" href=\"mobipreview.htm?18/41/19089\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A Vp &gt;50",
"    <span class=\"nowrap\">",
"     cm/s",
"    </span>",
"    is considered normal. Studies in animals and humans have shown that Vp is inversely related to the time constant of LV relaxation and is not affected by preload. Therefore, the presence of an abnormally reduced Vp can help distinguish patients with pseudonormal filling from those with normal LV relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/27\">",
"     27",
"    </a>",
"    ]. Furthermore, the ratio of peak E-wave velocity to Vp",
"    <span class=\"nowrap\">",
"     (E/Vp)",
"    </span>",
"    correlates with LV filling pressures, particularly in patients with depressed EF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2,28-30\">",
"     2,28-30",
"    </a>",
"    ]. In a small study,",
"    <span class=\"nowrap\">",
"     E/Vp",
"    </span>",
"    &ge;2.5 predicted a PCWP of &gt;15 mmHg with a sensitivity and specificity of 78 and 77 percent in patients with LVEF &lt;50 percent and 71 and 73 percent in patients with LVEF &ge;50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of Vp is subject to limitations, particularly in patients with normal LVEF. Patients with normal LV volumes and LVEF but impaired LV relaxation can have a misleadingly normal Vp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, some reports have shown that increased preload can increase Vp in patients with normal or reduced LVEF.",
"   </p>",
"   <p>",
"    Diastolic dysfunction as assessed by Vp may have prognostic value. In a study of 313 patients undergoing vascular surgery, Vp was an independent predictor of postoperative adverse outcomes, due primarily to an increased incidence of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interatrial septum bows in the direction of the atrial chamber with lower pressure. Normally, mean LA pressure is slightly higher than mean right atrial (RA) pressure and the septum bows to the right during most of the cardiac cycle. During inspiration, RA pressure rises higher than LA pressure, and the septum briefly reverses its curvature. Since RA pressure can be estimated using the inferior vena cava diameter and its change with respiration, as well as hepatic venous flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/33\">",
"     33",
"    </a>",
"    ], if the septal curvature behaves as described above and RA pressure is normal, one can infer the presence of a normal LA pressure. However, if RA pressure is increased and the septum continues to bow to the right, then LA pressure is likely elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ALGORITHMS FOR ESTIMATING LV FILLING PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with depressed EF, mitral inflow velocities can be used as the first step in an algorithm to estimate LV filling pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"     2",
"    </a>",
"    ]. When",
"    <span class=\"nowrap\">",
"     E/A",
"    </span>",
"    ratio &lt;1 and pulmonary venous flow shows predominant systolic filling, LV filling pressures are usually normal. On the other hand, with restrictive LV filling, LA pressure is increased. LA pressure elevation can be confirmed with a SFF &lt;40 percent. While most patients with pseudonormal filling have elevated filling pressures, it is preferable to confirm that conclusion by additional Doppler findings. These include the following: change in",
"    <span class=\"nowrap\">",
"     E/A",
"    </span>",
"    ratio with Valsalva,",
"    <span class=\"nowrap\">",
"     E/e'",
"    </span>",
"    ratio (average &gt;15),",
"    <span class=\"nowrap\">",
"     E/Vp",
"    </span>",
"    ratio (2.5), and PA systolic pressures (&gt;35 mmHg). A dilated LA is often present in these patients and should not be the final arbitrator in drawing conclusions about LV filling pressures in this population.",
"   </p>",
"   <p>",
"    When LV EF is normal,",
"    <span class=\"nowrap\">",
"     E/e'",
"    </span>",
"    ratio should be used as the initial screening step to estimate LV filling pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"     2",
"    </a>",
"    ]. When the average ratio is &lt;8, filling pressures are usually normal. When the ratio is increased (average &gt;13), LV filling pressures are elevated. For intermediate values, additional Doppler data are needed. These include LA volume (&gt;34",
"    <span class=\"nowrap\">",
"     ml/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    an Ar duration that exceeds that of mitral inflow by &ge; 30ms, and a PA systolic pressure &gt;35 mmHg in the absence of pulmonary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GRADING DIASTOLIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diastolic dysfunction can be graded from mild (grade I) to severe (grade III) with increasing likelihood of symptomatic HF and worse prognosis with higher grade dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with grade I (mild) diastolic dysfunction the following findings are expected: mitral",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio is &lt;0.8, predominant systolic flow in the pulmonary venous flow (S&gt;D), annular e' &lt;8",
"      <span class=\"nowrap\">",
"       cm/s",
"      </span>",
"      (septal and lateral), and",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio &lt;8 (septal and lateral). A reduced mitral",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio in the presence of normal annular TD velocities can occur in normal old individuals and should not be used to diagnose diastolic dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with grade II diastolic dysfunction, mitral",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio is &ge;1, and average",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio (septal and lateral) is &gt;10. In some patients with moderate diastolic dysfunction, LV end diastolic pressure is the only pressure that is increased and recognized by Ar-A duration &ge;30 ms.",
"     </li>",
"     <li>",
"      With severe diastolic dysfunction (grade III) restrictive LV filling occurs with an",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio &ge;2, DT &lt;160 ms, IVRT&le;60 ms, systolic filling fraction &le;40 percent, and average",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio &ge;13. LV filling may revert to one of impaired relaxation with successful therapy in some patients, whereas in others LV filling remains restrictive. The latter response predicts increased morbidity and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3362353\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography is the recommended imaging modality for the assessment of left ventricular (LV) diastolic function. (See",
"      <a class=\"local\" href=\"#H7123086\">",
"       'Summary of indicators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two-dimensional (2D) imaging is important to determine LV volumes, mass, and systolic function and left atrial (LA) volume. Patients with diastolic heart failure frequently have left ventricular hypertrophy, LA enlargement and increased PA pressures. (See",
"      <a class=\"local\" href=\"#H7123086\">",
"       'Summary of indicators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doppler measurements provide incremental prognostic information to clinical and anatomic findings (",
"      <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"mobipreview.htm?31/45/32470\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indicators of diastolic function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with normal LV EF, the initial step is calculating the",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Algorithms for estimating LV filling pressure'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A ratio &lt;8 is often associated with normal LV filling pressures and a ratio &gt;15 is indicative of elevated LV filling pressures.",
"     </li>",
"     <li>",
"      In patients with a ratio &gt;8 but &lt;15, other parameters are needed, which include pulmonary venous flow velocities, LA maximum volume index, and PA systolic pressure using the tricuspid regurgitation jet using continuous wave Doppler.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with depressed left ventricular systolic function, mitral inflow velocities can be used as the first step in an algorithm to estimate LV filling pressure (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Algorithms for estimating LV filling pressure'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When the",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio is &lt;1 and pulmonary venous flow shows predominant systolic filling, LV filling pressures are usually normal.",
"     </li>",
"     <li>",
"      On the other hand, a restrictive LV filling pattern (transmitral",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio (&ge;2), IVRT (&lt;70 ms) and DT (&lt;150 ms)) indicates elevated LA pressure. LA pressure elevation can be confirmed with a systolic filling fraction &lt;40 percent.",
"     </li>",
"     <li>",
"      While most patients with pseudonormal filling have elevated filling pressures, it is preferable to confirm that conclusion by additional Doppler findings. These include the following: change in",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio with Valsalva,",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio (average &gt;15),",
"      <span class=\"nowrap\">",
"       E/Vp",
"      </span>",
"      ratio (&ge;2.5), and PA systolic pressures (&gt;35 mmHg).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/1\">",
"      Paulus WJ, Tsch&ouml;pe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/2\">",
"      Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/3\">",
"      Rohde LE, Palombini DV, Polanczyk CA, et al. A hemodynamically oriented echocardiography-based strategy in the treatment of congestive heart failure. J Card Fail 2007; 13:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/4\">",
"      Appleton CP, Jensen JL, Hatle LK, Oh JK. Doppler evaluation of left and right ventricular diastolic function: a technical guide for obtaining optimal flow velocity recordings. J Am Soc Echocardiogr 1997; 10:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/5\">",
"      Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/6\">",
"      M&oslash;ller JE, S&oslash;ndergaard E, Poulsen SH, Egstrup K. Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: a serial color M-mode Doppler echocardiographic study. J Am Coll Cardiol 2000; 36:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/7\">",
"      Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988; 12:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/8\">",
"      Appleton CP. Hemodynamic determinants of Doppler pulmonary venous flow velocity components: new insights from studies in lightly sedated normal dogs. J Am Coll Cardiol 1997; 30:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/9\">",
"      Smiseth OA, Thompson CR, Lohavanichbutr K, et al. The pulmonary venous systolic flow pulse--its origin and relationship to left atrial pressure. J Am Coll Cardiol 1999; 34:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/10\">",
"      Klein AL, Tajik AJ. Doppler assessment of pulmonary venous flow in healthy subjects and in patients with heart disease. J Am Soc Echocardiogr 1991; 4:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/11\">",
"      Rossvoll O, Hatle LK. Pulmonary venous flow velocities recorded by transthoracic Doppler ultrasound: relation to left ventricular diastolic pressures. J Am Coll Cardiol 1993; 21:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/12\">",
"      Appleton CP, Galloway JM, Gonzalez MS, et al. Estimation of left ventricular filling pressures using two-dimensional and Doppler echocardiography in adult patients with cardiac disease. Additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction. J Am Coll Cardiol 1993; 22:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/13\">",
"      Kuecherer HF, Muhiudeen IA, Kusumoto FM, et al. Estimation of mean left atrial pressure from transesophageal pulsed Doppler echocardiography of pulmonary venous flow. Circulation 1990; 82:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/14\">",
"      Yamamuro A, Yoshida K, Hozumi T, et al. Noninvasive evaluation of pulmonary capillary wedge pressure in patients with acute myocardial infarction by deceleration time of pulmonary venous flow velocity in diastole. J Am Coll Cardiol 1999; 34:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/15\">",
"      Chirillo F, Brunazzi MC, Barbiero M, et al. Estimating mean pulmonary wedge pressure in patients with chronic atrial fibrillation from transthoracic Doppler indexes of mitral and pulmonary venous flow velocity. J Am Coll Cardiol 1997; 30:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/16\">",
"      Nagueh SF, Sun H, Kopelen HA, et al. Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J Am Coll Cardiol 2001; 37:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/17\">",
"      Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/18\">",
"      Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000; 102:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/19\">",
"      Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/20\">",
"      Dokainish H, Zoghbi WA, Lakkis NM, et al. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 2004; 109:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/21\">",
"      Kasner M, Westermann D, Steendijk P, et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 2007; 116:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/22\">",
"      Nagueh SF, Mikati I, Kopelen HA, et al. Doppler estimation of left ventricular filling pressure in sinus tachycardia. A new application of tissue doppler imaging. Circulation 1998; 98:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/23\">",
"      Sohn DW, Song JM, Zo JH, et al. Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr 1999; 12:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/24\">",
"      Ha JW, Oh JK, Pellikka PA, et al. Diastolic stress echocardiography: a novel noninvasive diagnostic test for diastolic dysfunction using supine bicycle exercise Doppler echocardiography. J Am Soc Echocardiogr 2005; 18:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/25\">",
"      Diwan A, Diwan A, McCulloch M, et al. Doppler estimation of left ventricular filling pressures in patients with mitral valve disease. Circulation 2005; 111:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/26\">",
"      Ha JW, Oh JK, Ling LH, et al. Annulus paradoxus: transmitral flow velocity to mitral annular velocity ratio is inversely proportional to pulmonary capillary wedge pressure in patients with constrictive pericarditis. Circulation 2001; 104:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/27\">",
"      Takatsuji H, Mikami T, Urasawa K, et al. A new approach for evaluation of left ventricular diastolic function: spatial and temporal analysis of left ventricular filling flow propagation by color M-mode Doppler echocardiography. J Am Coll Cardiol 1996; 27:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/28\">",
"      Garcia MJ, Ares MA, Asher C, et al. An index of early left ventricular filling that combined with pulsed Doppler peak E velocity may estimate capillary wedge pressure. J Am Coll Cardiol 1997; 29:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/29\">",
"      Rivas-Gotz C, Manolios M, Thohan V, Nagueh SF. Impact of left ventricular ejection fraction on estimation of left ventricular filling pressures using tissue Doppler and flow propagation velocity. Am J Cardiol 2003; 91:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/30\">",
"      Schwammenthal E, Popescu BA, Popescu AC, et al. Association of left ventricular filling parameters assessed by pulsed wave Doppler and color M-mode Doppler echocardiography with left ventricular pathology, pulmonary congestion, and left ventricular end-diastolic pressure. Am J Cardiol 2004; 94:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/31\">",
"      Ohte N, Narita H, Akita S, et al. Striking effect of left ventricular systolic performance on propagation velocity of left ventricular early diastolic filling flow. J Am Soc Echocardiogr 2001; 14:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/32\">",
"      Matyal R, Hess PE, Subramaniam B, et al. Perioperative diastolic dysfunction during vascular surgery and its association with postoperative outcome. J Vasc Surg 2009; 50:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/60/33735/abstract/33\">",
"      Qui&ntilde;ones MA, Otto CM, Stoddard M, et al. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15:167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5304 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-658DE962AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33735=[""].join("\n");
var outline_f32_60_33735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3362353\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATORS OF DIASTOLIC FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7123086\">",
"      Summary of indicators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Doppler mitral inflow velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pulmonary venous flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tissue Doppler imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Color flow mapping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ALGORITHMS FOR ESTIMATING LV FILLING PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GRADING DIASTOLIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3362353\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5304\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5304|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/6/42084\" title=\"diagnostic image 1\">",
"      Mitral flow velocities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/42/32423\" title=\"diagnostic image 2\">",
"      Filling patterns Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/1/39956\" title=\"diagnostic image 3\">",
"      Pulmonary vein velocities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/41/19089\" title=\"diagnostic image 4\">",
"      Flow propagation velocity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5304|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/21/3422\" title=\"figure 1\">",
"      Doppler normal diastole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/10/40109\" title=\"figure 2\">",
"      LV filling pattern mortality MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/8/38029\" title=\"figure 3\">",
"      Pulmonary vein velocity schematic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/44/17093\" title=\"figure 4\">",
"      TDE and diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5304|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/45/32470\" title=\"waveform 1\">",
"      Doppler diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?11/62/12262\" title=\"waveform 2\">",
"      Tissue Doppler",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20567?source=related_link\">",
"      Echocardiographic evaluation of the pulmonic valve and pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14378?source=related_link\">",
"      Echocardiographic evaluation of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_60_33736="Oropharynx of a snorer I";
var content_f32_60_33736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55998%7EPULM%2F67818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55998%7EPULM%2F67818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oropharynx of a snorer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The photograph is from a snoring patient in whom obstructive sleep apnea was excluded by polysomnography. Erythema and edema of the uvula are present, probably secondary to the tissue vibration that accompanies the snoring sound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oropharynx of a snorer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph is from a snoring patient in whom obstructive sleep apnea was excluded by polysomnography. Oropharyngeal narrowing is present in the lateral dimension due to residual tonsilar tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33736=[""].join("\n");
var outline_f32_60_33736=null;
var title_f32_60_33737="Posaconazole: Drug information";
var content_f32_60_33737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Posaconazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/7/20597?source=see_link\">",
"    see \"Posaconazole: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/18/35112?source=see_link\">",
"    see \"Posaconazole: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3339726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Noxafil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5222620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Posanol&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3339730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3339769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aspergillosis, invasive:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Prophylaxis:",
"      </i>",
"     </b>",
"     200 mg 3 times daily; duration of therapy is based on recovery from neutropenia or immunosuppression; initiate posaconazole in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) several days before the anticipated onset of neutropenia (eg, at the time of chemotherapy initiation) and discontinue once neutropenia is resolved (Cornely, 2007; NCCN, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Treatment (refractory to or intolerant of conventional therapy):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      U.S. unlabeled use:",
"     </i>",
"     200 mg 4 times daily initially; after disease stabilization, may decrease frequency to 400 mg twice daily (Walsh, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Duration of therapy should be a minimum of 6-12 weeks or throughout period of immunosuppression and until lesions have resolved (Walsh, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     400 mg twice daily; in patients unable to tolerate food or nutritional supplement, administer 200 mg 4 times daily; duration of therapy is based on severity of underlying disease, recovery from immunosuppresion, and clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Candidal infections:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Prophylaxis:",
"      </i>",
"     </b>",
"     200 mg 3 times daily; duration of therapy is based on recovery from neutropenia or immunosuppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Treatment:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Oropharyngeal infection: Initial: 100 mg twice daily for 1 day; maintenance: 100 mg once daily for 13 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Refractory oropharyngeal infection: 400 mg twice daily; duration of therapy is based on underlying disease and clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Prophylaxis:",
"      </i>",
"     </b>",
"     200 mg 3 times daily; duration of therapy is based on recovery from neutropenia or immunosuppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Treatment:",
"      </i>",
"     </b>",
"     Oropharyngeal infection: Initial: 100 mg twice daily for 1 day; maintenance: 100 mg once daily for 13 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Mucormycosis (unlabeled use):",
"     </b>",
"     Oral:  800 mg daily in 2 or 4 divided doses; duration of therapy is based on response and risk of relapse due to immunosuppression (Greenburg, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Cryptococcal infections:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Pulmonary, nonimmunosuppressed (unlabeled use): 400 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Fluconazole is considered first-line treatment (Perfect, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Salvage treatment of relapsed infection (unlabeled use):  400 mg twice daily (or 200 mg 4 times daily) for 10-12 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Salvage treatment should only be started after an appropriate course of an induction regimen (Perfect, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3339768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/18/35112?source=see_link\">",
"      see \"Posaconazole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aspergillosis, invasive:",
"     </b>",
"     Oral: Children &ge;13 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Candidal infections:",
"     </b>",
"     Oral: Children &ge;13 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3467267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3339770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-80 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ): No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ): No adjustment necessary; however, monitor for breakthrough fungal infections due to variability in posaconazole exposure.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3339771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-severe hepatic insufficiency (Child-Pugh class A, B, or C): No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Clinical signs and symptoms of liver disease due to posaconazole: Consider discontinuing therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3339777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Noxafil&reg;: 40 mg/mL (123 mL) [contains sodium benzoate; cherry flavor; delivers 105 mL of suspension]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3339728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3339773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Shake well before use. Must be administered during or within 20 minutes following a full meal or an oral liquid nutritional supplement; alternatively, posaconazole may be administered with an acidic carbonated beverage (eg, ginger ale). In patients able to swallow, administer oral suspension using dosing spoon provided by the manufacturer; spoon should be rinsed clean with water after each use and before storage.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3339731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     U.S. labeling: Prophylaxis of invasive",
"     <i>",
"      Aspergillus",
"     </i>",
"     and",
"     <i>",
"      Candida",
"     </i>",
"     infections  in severely-immunocompromised patients (eg, hematopoietic stem cell transplant [HSCT] recipients with graft-versus-host disease [GVHD] or those with prolonged neutropenia secondary to chemotherapy for hematologic malignancies); treatment of oropharyngeal candidiasis (including patients refractory to itraconazole and/or fluconazole)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Prophylaxis of invasive",
"     <i>",
"      Aspergillus",
"     </i>",
"     and",
"     <i>",
"      Candida",
"     </i>",
"     infections in severely-immunocompromised patients (eg, hematopoietic stem cell transplant [HSCT] recipients with graft-versus-host disease [GVHD] or those with prolonged neutropenia); treatment of invasive aspergillosis in patients refractory to or intolerant of itraconazole or amphotericin B; treatment of oropharyngeal candidiasis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F3339732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Salvage therapy of refractory or relapsed invasive fungal infections; mucormycosis; pulmonary infection (nonimmunosuppressed)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3339723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Noxafil&reg; may be confused with minoxidil",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Noxafil [U.S. and multiple international markets] may be confused with Noxidil brand name for minoxidil [Thailand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3339743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages reflect data from use in comparator trials with multiple concomitant conditions and medications; some adverse reactions may be due to underlying condition(s).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular:  Hypertension (18%), edema (9% to 15%), hypotension (14%), tachycardia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system:  Fever (6% to 45%), headache (8% to 28%), fatigue (3% to 17%), insomnia (1% to 17%), dizziness (11%), pain (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic:  Hypokalemia (&le;30%), hypomagnesemia (18%), dehydration (1% to 11%), hyperglycemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (10% to 42%), nausea (9% to 38%), vomiting (7% to 29%), abdominal pain (5% to 27%), constipation (21%), anorexia (2% to 19%), mucositis (17%), weight loss (1% to 14%), oral candidiasis (1% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (29%), anemia (2% to 25%), neutropenia (4% to 23%), neutropenic fever (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic:  ALT increased (6% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Rigors (&le;20%), musculoskeletal pain (16%), weakness (2% to 13%), arthralgia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory:  Cough (3% to 25%), dyspnea (1% to 20%), epistaxis (14%), pharyngitis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Bacteremia (18%), herpes simplex (3% to 15%), CMV infection (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system:  Anxiety (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal:  Dyspepsia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal hemorrhage (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (7% to 10%), AST increased (3% to 4%), alkaline phosphatase increased (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonia (3% to 10%), upper respiratory infection (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, adrenal insufficiency, allergic reaction, atrial fibrillation, cholestasis, ejection fraction decreased, hemolytic uremic syndrome, hepatic failure, hepatitis, hepatomegaly, hypersensitivity, jaundice, paresthesia, pulmonary embolus, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, syncope, thrombotic thrombocytopenic purpura, torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3339738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to posaconazole, other azole antifungals, or any component of the formulation; coadministration of sirolimus, cisapride, ergot alkaloids, pimozide, quinidine, or a HMG-CoA reductase inhibitor metabolized by CYP3A4 (eg, atorvastatin, lovastatin, simvastatin)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3339739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Azole hypersensitivity: U.S. labeling contraindicates use in patients with hypersensitivity to other azole antifungal agents; Canadian labeling does not contraindicate use, but recommends using caution in patients with hypersensitivity to other azole antifungal agents; cross-reaction may occur, but has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Hepatic dysfunction has occurred, ranging from reversible mild/moderate increases of ALT, AST, alkaline phosphatase, total bilirubin, and/or clinical hepatitis to severe reactions (cholestasis, hepatic failure including death). Consider discontinuation of therapy in patients who develop clinical evidence of liver disease that may be secondary to posaconazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Use caution in patients with an increased risk of arrhythmia (long QT syndrome, concurrent QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs, hypokalemia). Development of torsade de pointes has been reported. Correct electrolyte abnormalities (eg, potassium, magnesium, and calcium) before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI disturbances: Monitor closely for breakthrough fungal infections in patients with severe diarrhea or vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Monitor closely for breakthrough fungal infections in patients with severe renal impairment due to variability in posaconazole exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcineurin inhibitors: Concurrent use with cyclosporine or tacrolimus may significantly increase the whole blood trough concentrations of cyclosporine or tacrolimus and may result in rare serious adverse events (eg, nephrotoxicity, leukoencephalopathy, and death); dose reduction and close monitoring are recommended with initiation of posaconazole therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Consider alternative therapy or closely monitor for breakthrough fungal infections in patients receiving drugs that decrease absorption or increase the metabolism of posaconazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Midazolam: Concurrent use may significantly increase midazolam concentrations and potentiate or prolong sedative or hypnotic effects. Reversal agents should be readily available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients unable to take or tolerate nutritional supplements: Consider alternative antifungal therapy or closely monitor for breakthrough fungal infections in any patient unable to eat or tolerate an oral liquid nutritional supplement.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3339750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3339749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Posaconazole may enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).  Management: Consider vinca alkaloid dose adjustment.  Specific dose adjustment guidelines are not currently available.  Monitor response to vinca alkaloid therapy, including development of vinca alkaloid toxicities (e.g., gastrointestinal toxicity, neurotoxicity).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Posaconazole may increase the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Posaconazole may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: Posaconazole may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).  Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Quazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Posaconazole. Posaconazole may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Posaconazole may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cinacalcet.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Posaconazole may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Posaconazole may increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Posaconazole may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Posaconazole may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Posaconazole may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Posaconazole may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eszopiclone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Posaconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlipiZIDE: Posaconazole may enhance the hypoglycemic effect of GlipiZIDE. Posaconazole may increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This specifically applies to oral antifungal administration, and the interaction may be different depending on specific dosage form being used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Posaconazole. Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Posaconazole may enhance the QTc-prolonging effect of Methadone. Posaconazole may increase the serum concentration of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Posaconazole may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine.  Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Repaglinide.  Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Posaconazole may increase the serum concentration of Ritonavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Posaconazole may increase the serum concentration of Sildenafil.  Management: Concurrent posaconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Posaconazole may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Posaconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: Reduce tacrolimus dose to approximately one-third of original dose when starting posaconazole. Tacrolimus blood concentrations should be monitored closely during and at discontinuation of posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Posaconazole may increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Posaconazole may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Posaconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Consider temsirolimus dose reductions or alternatives to posaconazole.  Monitor sirolimus concentrations in all patients receiving posaconazole or any systemic azole antifungal.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Posaconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 2.5 mg per 24 hours  in patients receiving concurrent therapy with strong CYP3A4 inhibitors, such as posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Posaconazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Zolpidem.  Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3339753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Bioavailability increased ~3 times when posaconazole is administered with a nonfat meal or an oral liquid nutritional supplement; increased ~4 times when administered with a high-fat meal. Grapefruit juice may decrease the levels/effects of posaconazole. Management: Must be administered with or within 20 minutes of a full meal or an oral liquid nutritional supplement, or may be administered with an acidic carbonated beverage (eg, ginger ale). Consider alternative antifungal therapy in patients with inadequate oral intake or severe diarrhea/vomiting. Avoid concurrent use of grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3339733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3339734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Posaconazole has been shown to be teratogenic in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if the benefit to the mother justifies potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3339736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3339737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk has not been investigated; use only if the benefit to the mother justifies potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3339772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Give during or within 20 minutes following a full meal or liquid nutritional supplement; alternatively, posaconazole may be administered with an acidic carbonated beverage (eg, ginger ale). Consider alternative antifungal therapy in patients with inadequate oral intake or severe diarrhea/vomiting; if alternative therapy is not an option, closely monitoring for breakthrough fungal infections. Adequate posaconazole absorption from GI tract and subsequent plasma concentrations are dependent on food for efficacy. Lower average plasma concentrations have been associated with an increased risk of treatment failure.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Noxafil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (105 mL): $1085.11",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3339775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic function (eg, AST/ALT, alkaline phosphatase and bilirubin) prior to initiation and during treatment; renal function; electrolyte disturbances (eg, calcium, magnesium, potassium); CBC; breakthrough fungal infections",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Noxafil (AR, AT, AU, BE, CH, CN, CO, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HN, IE, IT, MY, NL, NO, NZ, PE, PH, PL, PT, SE, SG, TH);",
"     </li>",
"     <li>",
"      Posanol (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3339756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with fungal cytochrome P450 (latosterol-14&alpha;-demethylase) activity, decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting fungal cell membrane formation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3339758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Coadministration with food, liquid nutritional supplements, and/or acidic carbonated beverages (eg, ginger ale) increases absorption; fasting states do not provide sufficient absorption to ensure adequate plasma concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 465-1774 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98%; predominantly bound to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not significantly metabolized; ~15% to 17% undergoes non-CYP-mediated metabolism, primarily via hepatic glucuronidation into metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 35 hours (range: 20-66 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces 71% to 77% (~66% of the total dose as unchanged drug); urine 13% to 14% (&lt;0.2% of the total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cornely OA, Maertens J, Winston DJ, et al, &ldquo;Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients With Neutropenia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(4):348-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/17251531/pubmed\" id=\"17251531\" target=\"_blank\">",
"        17251531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eiden C, Palenzuela G, Hillaire-Buys D, et al, &ldquo;Posaconazole-Increased Vincristine Neurotoxicity in a Child: A Case Report,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2009, 31(4):292-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/19346885/pubmed\" id=\"19346885\" target=\"_blank\">",
"        19346885",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al, &ldquo;Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer: 2010 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(4):e56-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/21258094/pubmed\" id=\"21258094\" target=\"_blank\">",
"        21258094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenberg RN, Mullane K, van Burik JA, et al, &ldquo;Posaconazole as Salvage Therapy for Zygomycosis,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2006, 50(1):126-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/16377677/pubmed\" id=\"16377677\" target=\"_blank\">",
"        16377677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herbrecht R, &ldquo;Posaconazole: A Potent, Extended-Spectrum Triazole Anti-Fungal for the Treatment of Serious Fungal Infections,&rdquo;",
"      <i>",
"       Int J Clin Pract",
"      </i>",
"      , 2004, 58(6): 612-24.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating G, &ldquo;Posaconazole,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(11):1553-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/16033292/pubmed\" id=\"16033292\" target=\"_blank\">",
"        16033292",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krieter P, Flannery B, Musick T, et al, &ldquo;Disposition of Posaconazole Following Single-Dose Oral Administration in Healthy Subjects,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2004, 48(9):3543-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/15328123/pubmed\" id=\"15328123\" target=\"_blank\">",
"        15328123",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prevention and Treatment of Cancer-Related Infections,&rdquo; Version 2.2009. Available at file://www.nccn.org/professionals/physician_gls/PDF/infections.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, &ldquo;Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perfect JR, Dismukes WE, Dromer F, et al, &ldquo;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(3):291-322.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/20047480/pubmed\" id=\"20047480\" target=\"_blank\">",
"        20047480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raad II, Graybill JR, Bustamante AB, &ldquo;Safety of  Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2006, 42(12):1726-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/16705579/pubmed\" id=\"16705579\" target=\"_blank\">",
"        16705579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skiest DJ, Vazquez JA, Anstead GM, et al, &ldquo;Posaconazole for the Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Subjects With HIV Infection,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44(4):607-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/17243069/pubmed\" id=\"17243069\" target=\"_blank\">",
"        17243069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tomblyn M, Chiller T, Einsele H, et al, &ldquo;Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: a Global Perspective,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2009, 15(10):1143-238.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/19747629/pubmed\" id=\"19747629\" target=\"_blank\">",
"        19747629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ullmann AJ, Lipton JH, Vesole DH, et al, &ldquo;Posaconazole or Fluconazole for Prophylaxis in Severe Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(4):335-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/17251530/pubmed\" id=\"17251530\" target=\"_blank\">",
"        17251530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vasquez JA, Skiest DJ, Nieto L, et al, &ldquo;A Multicenter Randomized Trial Evaluating Posaconazole Versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects With HIV/AIDS,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2006, 42(8):1179-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/16575739/pubmed\" id=\"16575739\" target=\"_blank\">",
"        16575739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al, &ldquo;Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(3):327-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/18177225/pubmed\" id=\"18177225\" target=\"_blank\">",
"        18177225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh RJ, Raad I, Patterson TF, &ldquo;Treatment of Invasive Aspergillosis With Posaconazole in Patients Who are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44(1):2-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/60/33737/abstract-text/17143808/pubmed\" id=\"17143808\" target=\"_blank\">",
"        17143808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9479 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33737=[""].join("\n");
var outline_f32_60_33737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339726\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5222620\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339730\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339769\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339768\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3467267\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339770\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339771\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339777\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339728\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339773\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339731\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339732\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339723\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339743\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339738\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339739\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339750\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339749\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339753\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339733\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339734\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339736\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339737\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339772\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322953\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339775\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038888\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339756\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339758\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9479\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9479|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/7/20597?source=related_link\">",
"      Posaconazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/18/35112?source=related_link\">",
"      Posaconazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_60_33738="Nail anatomy 3";
var content_f32_60_33738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85616%7EPC%2F76994%7EDERM%2F83965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85616%7EPC%2F76994%7EDERM%2F83965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Anatomy of the nail apparatus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 598px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJWAesDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxvGeqT6H4O13VrRY3ubCwnuollBKFkjZgGAIOMjnBFbNVdVsLbVdMvNOv4/Ns7uF7eaPcV3o6lWGQQRkE8g5oA5Ww8a+T8MdE8Vavboz3llb3E8cE0MCK0iBjhp5UUKCT1fP1rjH+NR1XUPCJ8KaPc3lhqt/cWN0soi80PEgbbGfOCZ5DbiSpHQ54rsW+F3hR9Kg0yW11GWwt2ie3hl1a8dbdo/uGLMp8sqOAUxxx0p8fwy8Jx20MMWnTx+TfSalHKl9cLMtw4AeQSiTf8wAyM4PpQBzafHjwhJq9xYRG8k8tbopMnklZTAhdwE8zzFyAdpdFDEHBqZfjPo58Lp4gk0TXLbTpD+7a9FtaGVdgfdGJp08wc4+TdkjjsT0qfD3w3G975FreQQ3plNxawajcxW0hkUq5MCyCPJBP8PXnrzSXvw68L3lnotrNp0ix6NC1vYtDdzRPDGyhGTejhmUqMEMTkdetAHOeFvHc3ib4p2EGl3Uh8N3vhYarFbyRKrCY3Xl7icbgdvGM4/nVvVPi3ouma3f6dc6dq5Sx1CDTbm7SKIwxyzDKH/WbyvuFOPTpnofD/gfw94evrS80fT/s9xaWH9mQv50j7bbzPM2YZiD8xzk8++KpN4I8Ia5HeXy2Ud3Fql1DqE00d1IVmli4jcENgY9BgHuDQBkan8W9FsfFUvhueG4g1M/aFik8y2uE3RIW+ZIpzImQMgOqE9OOcZvgHx3qXib4h6Tb/a9+j3vhUap5P2RYMzm6Me/G52X5eNvmMO/WulT4W+D47/7YmlOsonlulQXk4iSWVSsjLHv2KWBwcAdvQVpaB4J8PeH760vNI0/7Pc2lgNLhfzpH2W2/zNmGYg/Nzk8++KAPOb/4nXWk/Ezxgmt/2nFoGgx2kMVpaw2zefNODt3EkyFnJBQKQAAd+3va8UfE6a5n0O10P7ZpWoxeKrHSNVs7uKFpBFKHYrlS6YYDhlbPB5FdxqXgPw1qc+uzX+lpPJrghF+Wlf8Ae+SMREfN8hXsVwe/WooPh34XhjgUaa7tFqMerCaW6mkla6QEJI8jOXfAJGGJHtQBw4+KE/iD4j+BrTw4L2Dw7qFzqNvPNPDEEvzBFkGPkyKFcHkhM57849krz258L/DzwZqum6vfy2WjTwTzzWJvNUeKGOSUYl8qN5PLGQeQq46cdK7qwvbXUbOK80+5gurSZd0c0EgdHHqrDgj6UAWKKKqapqVjpNjJe6re21jZx4Dz3MqxRrkgDLMQBkkD6mgC3RRRQAUVlx69psniSbQEuc6vDbLePB5bcRMxUNuxt6gjGc+1alABRTJpY4YXlmdY4o1LO7nAUDkknsKx9M8V6Hqusf2XpmpQXd59kW+Agy6NAzFQ4kA2EEgjg5oA26KxoPEulXHia60C3nll1S1RJLiOO3kZIQwyoeQLsUkchSwJHapda17TdEn02HU7nyJNSuVs7UeWzeZKQSF+UHHAPJwPegDUorKvvEOl2PiDTdEurrZqmpJK9rD5bHzFjGXO4DaMA9yM9q1aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqrqt39g0y8vNnmfZ4Xl2Zxu2qTjPbpXj3g3482viWfw9af2G9pqOp332Wa2e6ybeNo98cwOwb1YZ9MEH2yAe10VwmrfFDw/Z22pBJ5IdQsrM3xttUs7ux3Qhtpf5oSxXPGVVvpTvBHjC88Q+NvFukzRWi2OlR6fJbPCH3OLiAyNuLdQD0+VeOooA7miuLg+Jnha8vBY2OpM15JLNbQ+baTxxSTxA74xIyBCwx0DZPGOorH8JfFOyk+HOieIvF/m2Ul7bmeaW0065ktYv3hQbpFV1ToPvN3oA9Morzmx+LGjyeK/FWl38UllYaFFBOdSdJTFKkke8lv3YEfYLlj5mcrmup8L+LdG8UNeJo11JLLZlFuIZreW3li3ruTckiqwBHIOMGgDdooooA5/x/qc2j+DdWu7M/wCmiExWvOMzyERxD8XZRWjoGmQ6JoWnaXa/6iyt47aPjqqKFB/SsDxhnUPE3hXRl5Q3L6ncD/plbqNv/kaSA/ga66gAooooAKKKKAPN/il4b1/WvF3gW+8OpbqNMvJ5bi5uFEkcCtHtBMfmIz5ORhTmuX0/4Wa7o/iHw7pWna/rsHhqCC4nv7qwvFtRLdNN5gUxZOFPTgHjjPJr3CigDw3w14f+Idvr9jLrDaxMI3vzq839qg29/G4PkJaxCUeSw4wcR7Tzk1h23hf4rp4R8S291Lrsusz21uNJlXW0/wBHQXAZ4XIdczbOsvO4ZXd2P0dRQB4brHhbx/ceJby7t7jWVtn8UW7xiPWCkY0ooRNiMSgAZxgY3jqorNv/AA98T/8AhG00uO21OWRby/EN8NbkNxDC2Ps+dt1EH5/ikaQqAfkPQ/QlUtb1KDR9Gv8AU7s7bazgkuJT6Kilj+goA8x+GnhzxVaeN7XWvFNs/mN4YtrC4uHnjdmuklLMp2sSTjB3dD61l6p4a+ILeJb7UbO41cKPE9tNbINVxCdN2/vgYjJs25x8pXd6DrXrXhRtRfwzpT624fVHto3uiFCgSFQWAAA4BJH4Vq0AeC22i/E1/H6X32W/sdKc6hHcQLqzzQsrRN9ndfMuXOS+MBYotnoR02PhN4W8V6Z4vtNV8VQTmQ+GoLGe5nukmdrlZ2ZlYhiSdpB3dPevYqKAPCNX8B+MINb+JmqeHTe213qtxaNYyLqRVriEAGdUy5Eb8bVZgNo4UqppIvB/jW71fSLi5tr7+yLTxRDf2trqN+lzc2dqsTK7PIZH3AsRhQ7Ec17xRQB4D4F8HeNU+IPhDWPFNnqU11p/9orqWoXOoxzQuZciIwR+aSibcDARfcV79RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQX9ql9Y3NpKWEc8TRMV6gMMHHvzXnkHwZ8MQXfha7ifUUu/D0Jt7edJVV505wJSFGcZbBXaRmvSqKAPILX4AeFreO7UX+sMbmzlspJC1urskjh2LMsILvkcM5Y4454x3Xhjwbp/hzW9Y1Sxmu5LjVI7WKZZmUqot4vLTaAoIJHXJPPTHSulqK7uIrS1mubhxHBCjSSOeiqBkn8hQB5N4K+EBsbs3fibUprl7fVbzUbK0tZFFvGZuA7ZjDmQDsWKjsOuXX/AMBPDF9pen6fNf6ybeysW0+MM8EnyFy+8B4mCSZP30CnAx657zwBNfXXhDTb3VnkN5eobx1kGDEJWMix47bFZU/4DXQUAedXnwi0C8k1nz7rUza6xZ29lfWvmR+XKIECwyZ2bldcA/KwBI5BrZ8A+BNN8Ex3SaXIZBcCNWLWdpAcJuxkwQxlvvHl93tjJz1lFABRRUV3cRWlrNc3DiOCFGkkc9FUDJP5CgDldA/4mXxA8SakRmKwjg0mE9twXzpSPqZY1PvH7Guvrlvhlbyx+DbK6ukKXepF9SnVuqvO5l2n/dDhf+A11NABRRRQAUUUUAFFFFABRRRQAVyHxIP22z0nQRydZ1CK3kX/AKYJmabPsUiZP+BiuvrkI/8AiafFGZutvoenCMc8efctub8VjhT8JfegDr6KbJJHGMyOqj/aOKqSarp0ZxJf2in0Myj+tJtIaTexdorLfxDpS/8AL9E3+7lv5VA3ijSB/wAvLE+0L/4UueK6lKnN9GbdFc+3i3TB93z2+kZH86jPjCxB4t7w/RV/+Kqfaw7lewqdjpKK5g+MbX+Gzuj9do/rTD4xi7WM34uKXtodx/V6nY6qiuUPjAdrBvxl/wDrU0+MH7ad/wCRv/saPbw7j+rVOx1tFcj/AMJfL/0Dh/3/AP8A7Gj/AIS6Y/8AMOX/AL/n/wCJo9vDuH1ap2Ouorkv+Etn/wCgen/f4/8AxNKPFc5/5cE/7/H/AOJo9vDuH1ap2OsorlR4pnP/AC4p/wB/T/8AE04eJpz/AMuUf/f0/wDxNHtodw+r1Ox1FFc0viSc/wDLmn/f0/4U8eIJj/y6J/38P+FP20O4vYT7HRUVgrrkx/5dk/77P+FSrq8p/wCWCf8AfZ/wo9rEXsZ9jZorMTUpG/5YqP8AgX/1qmW9dv8Almo/Gq50S6ckXaKrrOx/hA/GpQ5PancmzH0UgNKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuR+J5a58ORaLG22XXLqLTOOvluSZse4hSY/hXXVyFx/xNPihaxY3QaHp7XDenn3DFE/FY4pfwkHrQB1yqFUKoAUDAAGABS0UUAFFBIAyTgCsu91/S7MkT30IYfwqdx/IZpNpbjUXLRI1K5L4oMZ/C/9kxlvN1q5i0wYODslbEp/CISn8KW48c6ehxBBcze+0KP1Of0rhta8ZXGqePdJS2s40TSbeW8IkYuPMlBijPGMfJ54/Gs3WgupssNVfQ9kVQqhVACgYAHQUteXT+J9auP+XpYQe0UYH6nJ/Ws+a5vrjP2i8uZAezSsR+WcVm8THojdYCfVo9cnuYLcZuJ4oh6u4X+dUJfEOkRnB1C3Y/7Db/5ZrytbYZzt5+lTLbH0qHiX0RosDFbyPRZfFekJ0uGf/djb/CqknjWwH+rgun/4Co/ma4tbbHapFtqXt5lLCUl3Onk8br/yy0+Q/wC9IB/IGq0njW7P+qsoV/3nLf0FYoth6VKtt7VPtaj6lLD0l0Lz+LNWf7q20f0jJ/marvr+sydbwr/uRqP6U1bb2qRbYUueb6lezpraKKr3upS58y+ujn0kI/lXL+BlnvNMudWeaV21a5kuwS5O6PhIvr+7SOtjxy0lr4VvVtTtu7oLZW59JZmEaH8C4P0Fbmn6bFY2VvaWybYII1ijX0VQAB+Qpa21FeN9EZYslJyUGfpUq2n+zWyLf2p4gpcpXOY4tP8AZp4tPatgQCnCAelHKTzmQLT2pwtfatYQj0pwhHpT5Rc5ki19qcLQela3kil8oelHKHOZQtR6UotfatURD0pRF7Ucoucyxa+1L9lHpWp5XtSiL2o5Q5zMFsPSnC2HpWl5XtS+VT5Rc5ni3HpTxbj0q8I6cI6fKLmKSwD0qRYfarYQU4J7U0iXIrrEPSp0jqQKKkVatIhsREqdFpqiplFaIybJEFSrUa1KtaIyY8UopBS1SIFooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiq1/fW1hAZr2eOGMcZc4yfQepobsNJvRFmuN+HsqXFjrPiK4dFXVr+WdHYgAW8eIYuemCkQf8A4Ga534i/ESa18PX6+H4T9okUW8E8mQfNkIRNqjn7zDr+VYNjavBptlY+ZI9taQpBCjHhVRQqgDoOBXPPERW2p10sFOb97Q9M1LxpplqStuXvJP8ApkPl/wC+j/TNc3eeM9VuGItkhtU7YG9vzPH6VixWh9KtR2ntXPKtOXkdsMLSh0v6lW7ub2+JN5dTTA/wsx2/l0qJLbjgVrJa+1TLbe1Z2b3NuZRVkZC23tWJ4Qt/tlzrWqYytzeNDEf+mcP7ofhvWQ/8CrpPEl0NG8PajqO3c1tA8iJ/fcD5VHuTgfjU/hfR/wCx/D+naexDPbwJG7dd7gfM31JyfxqlGyM5VLtDEtfap0tfatMRCniMU7Cc2Zy2o9KlW39qvhBTtop2J5mUhb+1OFuPSrmBRRYV2VhCB2pwiHpU/FLRYLkSxCpBGKcDTxTEcrraC/8AGnh/TgN0VoJdTm9MqvlRg/VpWYf9c/aurCCuY8KH7f4h8Sas3KG4XToD/wBM4Ad3/kV5h/wEV1QNU0ZruAQU4JSg0opAIFFLtFOFKKBDQgpwQUop1OwDdo9KacZqQ9KiJ+agB6rxT9tKo4FLQIbto24p2KMUAJijApaQN82O9MQYpcUtKKAEApwFApRTEKBTwKaKeKpEseKetMFPWqRmyVakFRKakWrRmyQU6minCrRAtFAopiCiiigAooooAKKKKACiiigAooooAKKK878Z+L5Hml03R32quUmuB1J7qv8Aj+XrUTmoK7NaNGVaXLE2PE3jK301ntrALc3o4PPyRn3I6n2H6V59dT3eqXRuL+Zppe2eij0A6AVFa2wXBIrQijArz51JVNz2qOHhRWm/c5vVLf7b4m0PTgMpCZNQmHsg2ID9XkDD/rma7GG36VznhfZd+INe1RsbBKmnwk90hB3Een7x5B/wEV1a3ES/xCi3QXM3dksUAA6VOsQqr9vhXuKT+1Ih3p6ENMviMU4KBWd/akdB1NPWnoLlZleMgLy80DSBgi7vlnmH/TKD96fw3rEp/wB6unGK4e01FL7x7f3R5j020Syj9pJSJZP/AB1YK6VdSQ96pvoKMG7s1N1G6qC3iN3qdJlboaQ+Us7vel3VCpzTs0xWJN1G6oxS0BYfmlzTM0uaBWJBVPXdSj0fQ9Q1KfmO0t3nYeoVScfU4q0GrmfHBF7/AGNoo5/tG/j80D/njF++fPsfLVP+B01uTLRGp4L06TSfC2m2dyd10sQe4b+9M53yH8XZj+NbYqMGng5ouK1iQU4GogaeDQJokBpRTAacDQSx4p1MzThTEI5wKpSSb5FiU8v19l7/AOH41JeSbRVbTMySySn12r9B/wDXzSb1sUlpc1lwAAOlLTaM0yB2aKYzYpsMgkTcucZI59jigLEmarO2L6I9trL+PB/pVis+4crcxMeiuP14/rQxpGjmlBpmeKM07kkgNOBqLNOBpisSing1EDTwaZLJQaepqIU8VSJZMpqQVCpqRTVozZMKcKjBqQVaM2LS0lLVEhRRRQAUUUUAFFFFABRRRQAUUVh6jrLfvItOVXkHHnPyin2H8X6fWk2luOMXLY5v4j+KDaZ0mwkxO4zPIp5RT0UehP8AL6153Dcxx4UY3dgOtdcnha3815rtpbq4kYu8krfeYnJOBT7myisowlvEiSP90KoAHua4pxc3dnr0JwpR5Yo5Zr2VWVRFJuPQbcH9ar6tqdzp+lXl9KgWO3iaUgtycAnHHc11FtpRJJOSx5LHqTWV4t037TLoujquft96hlH/AExi/evn2JRU/wCB0RpIqeIdjH8M6Zf2Gg2VtNKBMqb5iF5MjHc5692LGtUWdwfvTSn8hXZJpi+lSrpyjtVciI9tZWOKGnO3UyH6saeNMP8AdP4mu1GnqP4acLFR/DT5EL2xxP8AZZPVP0o/sr/YH5V232JfSkNovpT5Q9qcUmkKhYrEqljkkLjJ6ZP5Cn/2afQj6V15tl9KjaBR2pco1VOT+wyp915B9GNCm8hOVlLezDNdNJAtVJoBg8UuVFKoZ0GsTRNieIkeqn+la9nqVvcnakg34ztPB/KsieADtVGSMq6lB8+fl+tTylXTOzDA9KXNZ2mySSw4+9Kgy0fc+6+v0q9GwdQVOQaQh+aUGmmkzQBIDXNWp/tH4hXk+Mw6TZLaqf8AptMRJIPwRIf++jXQlgqksQAOSTXOfD0NNoL6pICJNWuJNQ5HOxziL8oljH4UImS1SOsU1IpqBTUimgTRMDTgaiU08GgkkBpwNRg04GmSySnA8VGDTmOFoEzN1OXarH0FWtMj8q2QHkgcn1NZt8fMuI09WB/LmteAYjAqVuXLRE+aM03NITVGZHcvtSodMfdbn/fb/wBCNMvm+Q1Ho7fuW/32/maV9S7e6aeazr/K7mHJxkfUdKvk1Tvfu5oewo7ltH3ICDwRmlBqnp75tUB/h+X8uKsbqaZLRMDTgagDU9Wp3FYnBp4NQK1SA0yWiZTUimoFNSKatMlonU1IhqBTUqmrRm0TrUgqFTUi1aMmSClFIKBVEi0UUUxBRRRQAUUUUAFFFR3MoggeQ87R09T2FAGfqkzSubWE4XH71h6H+Ee57+31qotsqqAAABxgVZhjKpl8F2+Zj6k9aftrBu7N0+VWRRkiRFLNwoGSaw/K8+ZpWBy3QHsOwrZ1ZvkSEfxnLf7o/wDr4qtBH3NSaxelxsNsqjpXPadGNR+Imp3PWHSLRLGP0E0uJZf/ABwW/wCZrrJGjhheWVgkaKWZjwAAOSa534bRM/hiPUp0KXGryyam4YcgStujU/7sflr/AMBqkJu50YQUbalxRigLkW2jZ7VLRQFyApTWQVYNRvQO5UdaryLVySq0lItMqOOaryLmrbjmoJBxSNEzLuVycCpNMsPO/fMOD936f/XpzRedMsf948/Tv/h+NdLaW4SIDFK1wlOyMKW3aB1ki+V0OVNXHCzW/wBtgUq3/LaMeo6n6/zFXLyHKnis7TpPs9+YycRyjH/Au3+FKSHGVx+QQCDmm0ssfkXMkQ+799B6A9vzz+lIw4rI2TOd8fzyJ4Wura3cpc6gUsIWHUNMwj3D/dDFv+A1v2sUdtbxQQKEiiQIijoFAwBXNasft/jfRbHrHYRS6jIP9sjyov0eY/VRXTA0PYFq2yZTUimoFNPU4oBosKakBqBTUgNMhkoNKKjBp2aCbEq0THCGmqaZdNiI0E21MtP3mo5/ur/M/wD1q2kOFFYtid11KfQhf0z/AFrYB4pRLmPzQTTc0maZFirf/wCrNRaOf3T/AO+386kv/wDVGq+kN8so9H/oKnqX9k1SarXnMJqXNQ3PMTU2StyDTH4lX0bP5j/9dXM1k6c+LqRfVR+hP+NaZNEWOSsyUNTlNQA04GncmxYU1IDVZWqVWqkS0WFNSKarg1IpqkyGiypqVTVdDUymrRm0WENSrUCGplrRGTJFp1NFOqzMWigUUxBRRRQAUUUUAFUNRbfNBD7mRvw6fqf0q/WdcENeyEfwqqH9T/UVM9io7gKDRmmsaxNDIvWEl7Jj+ABP6/1FSQjAqqrbnkf+87H8MnH6YqyjYFCNbHP/ABHkZ/DL6ZC5S41eaPTEK9QJW2yMPdY/Mb/gNdPEqQxJHEoVEAVVHQAdBWTqGmxXuraXfSyPnT2kkjjGNpd0Kbj7hWcD/eNaBkphYsbqbuFQGSmmT3oCxZ3Um+q3mUhkoHYsF6jZ6hMlRPJQFiSR/eq0j0jyVXkepLSHO9QSNxSM9Qu+aRokWdLjEl07/wB3Cj+Z/pXRpworB0P7m7+8Sf1rb3cU0ZT3I7nlTXPagpB3LwwIIPoR0renbg1kXgypoY4aE96yyxWt0vAOPyb/AOvioz0qO3PmaHKvUxFsfgdw/mKfnIyOlYs6YmZbaZHbaxqGo72ee8WJDnHyJGDtUe2Wc/VjV/NDdaaTUtmiQ8GnqahB5p6mgTJ1NSqarg09WoJaJweaeDUQalBpkk6Gob1v3Zp6Gq98fkND2JS1KWlnLSN6uf04/pWwGrF0k/I3++3/AKEa1s8Uo7FTWpLupN1R7qM0ybEd7zEap6U3zzD/AGgf0FWbs/uj9KoaY37+b8DUvctL3TXzTJTlD9KbvoY5Q0ybGVbNt1FfcMP5VrFqw92NRj+p/lWqWqYlzRNupweq+7FAfFVcixbVqlVqpq9Sq1UmS0XFapVNVEaplaqRm0W1NTIaqoanQ1omZyRaQ1MtVkNWErRGMiZafUa08VojNjhRQKKZIUUUUAFFFFABWOrbrq7P/TXH5KB/StisRT++uP8Arq386iexcCfNMdsA0m6opT8p+lZGiRiwP+4iP+yP5VOJOKoQv+5j/wB0fyqTzOKSOixaMtIZaqGSkMlFx8pa82kMtVfM96b5lFw5S35lNMnvVXzKQyUXHylkyVG0lVzJTGkouPlJXkqF3qNpKiZ+KRSQ9nppbmoWemiTmkVY2tFOLeP/AHRWtvrB0aT9yo9OPyrWDcVSMZLUWZuKz7o5U1bkPFUrk/KaGEUZV7rC6JpL3M8Jeza7WK4lDY+zo6hRIR3AbaD0wCT2wdS3bNvGc/wj+VQWkEN7p2oWt3Es1tODHJG4yHUrgg+2K53wLeTRWs2h6jIXvtNVVSRjzPbsD5UnucAqx/vI3qKykbx0Z07Hmmk0jNTC1Zm6RIDTgcGod1ODe9ArFhWqQGqqtUobNFyWiwGpwaoAaUNTJsWVaq963yU4NUF23yUmxJakGkn5G/32/wDQjWmGrJ0s48wejn/GtLdQthyWpLupN1RlqbupisFy37o1Q044uZf91f61auG/dmqVkf8ASJP91f5mpe5SWhqZ9aC3ymod9IW+U07isZkpxqER/wBv+hrV3CsaZv8ATYv9/wDoa0S1TEuS2Ji1JvqAtRvp3IsW1epkaqKvUyNTuS0X0apkNU42qdGq0zNouIelWIzVNGqxGa0RlJF2M1YQ1UjNWY61RhIsLUgqJakFaIyY4UtJS1RIUUUUAFFFFABWC42Xl2vbzc/mqn+tb1Yep4TUHx/GisfryP6ConsaU9xC3FQyvTWfioJXrI3UTEjfEaDPRQKcXqq7bZZF9Hb+Zo31J0pFgyU0vVcv70wyY70DsWi9JvqoZfemmWlcfKWzJSGT3qmZaaZaLhylsye9RtJ71WMlRtJQPlLDS1G0lVmkphkpDsWC9MMmKgL0xiaCrGxpE2JHX3yPof8A6+a30fIrjrSXy7hGJwD8p/p/n3rpreTcg5poynEp6ZrBvNW1TTbmH7Pd2TqyruyJYXGUlHHQkMpHYqfYm1d8KawfGcUti1r4ksY2e403d9ojQZae0bHmpjuVwHUeq4/iNbE1xFcWqT28iyQyqHR1OQykZBB9CKpmcd7DNNk22t42ejn/ANBFc14oiksIrDxDZoz3Gmpi4jQZM1q2PMXA6lcB1HquP4jW3CxXSbhu8rsB+i/0qwSAuPasG9TqUbobFcR3EMc0EiyQyKHR1OQykZBB9MUFq5Tw439iarc+HZOLYA3Wmk9PJJ+aIf8AXNjgDsrJ6GulLVD0NI6om3U4NVbdTlalcqxZDVKretVVanhqLktFoNShuarhqcHp3IsWd/FQ3DZU0B6jlOQaGCRFpzYkm/3/AOgrQ3Vl2jYuHHsD/Or26kgktSUtSbqj300tTuKw+U/Iap2hxPL9F/rU0jfKaq2p/ey/gKlspLQvlqRn+U1EWpjNwadwsUnObyL/AHv6Gr5as4n/AEpPqT+lWy3FSmVJEhakDVCW5pA1MmxaVqnjaqSNU6NVIlovxtViNqoxmrMZqkZSRejNWojVGM9KtxGtYmMi7GelWo6pxGrcdbROeRZWpBUSVKK0RixwpaQUtUSFFFFABRRRQAVj6+hWS3m7cxn8eR/I/nWxVTVIDcWEqL98Dcv1HIpSV0VB2kmc6zVBK3FODBlDDoRmopK5ztSMK9+S8l/28N+mP6VFvqxq6Yljk9QVP8x/WqS1J0R2HlqaWoNMYUigL00vSEU0igYpekLUhFJigBC1NJp2KQrQBETTalKUmykBHQQakCU4R0DIccEHoa2dLuSybX++vB9/eszZSozROHT7w7eo9KewmrnUhgV56VwmlSjQb+88OynbaxqbrTSf+eBPzRD/AK5scD/ZZPQ11EN4rxBs1y3jW1m1CCCfT1VtSsZPtNuCcB8A7oyfR1yvtkHtVX0MuV3udI/yQWcB+8B5j/X/APWaVn4rN0jU4dYsIdTtiTDcoGjyMEL6H0Oc5Hbp2q2WrlbOuC0uYvi2xnu7GO604D+1LCT7Ta5ON7AYaMn+66kqfqD2q9pGpQarpttfWhJhnQMoYYK+qkdiDkEdiDVgmuZsw2ieJ5LMA/2dqrNPBgcRXIGZE+jgFx7h/Wi91Yprld+51QNKGrj08UXl7rupWGjaUt3DprpHczSXQiJcjJWNdpDED+8VGeM96st410FXCfbWZzePp4VbeViZ0GWQALyeRz0PYmlysOePc6pWp4bivPPDvxFg1fRdHv3tVsjf3ZtDHO0oAOWxscRbXOFz/CB0LAineKfiDb23g7UtX8OE3clsEMck1pMLdwZVjOJCFVvvH7rdvrVckr2sZ+0hbmuehh6eHrl38Y6HHrA0xr7/AEszi14icx+cRkRmTbsD4/hzmuh3VLutylZ7FkPQzAiq4al3UXDlGK2y7X3BFXN9Z05w8bejD9eP61aD8daSYNE27mgvUO4UhancViRm+U1Xtm+aU/7X9BTieKitzhWPqx/nSKsWt1MLUwtTWbigLEGc3Q9lNWC1VYzmWRvTC/1/rUpNIbQ4tQG5qMmgGmTYsI1TxtVVDU6GqRLRcjarUbVRjNW4jVoykXYj0q7Caoxdquw1rE55l2KrkXSqcNXI62ic0iylSCo0qQVqjFjxRSClpkhRRRQAUUUUAFFFFAHKajCba+ljxhGO9PcH/A5H5VUfpXSa7aG4tPMjGZYcsvuO4/H+YFcwHDKCDkHmsJqzO2lLmiU9Qi823dVGWHzL9RWMuDgjoea6J+axLiLyrll/hb5l+ncfgf6VmzoiyPbmkKVMlPxQXcqlKaU9qtlfakK0BcqbPal2VZK0bRQFyt5dJ5ftVg4pCVFAyDy6Ty6lLqKjaZRSANlLtFQvdKO9QPeqO9A7MtsBUEpAqlJfjtVSW9LNtXLOeiryaTZSiyzcXBiJeNsHuOxp+n77rMrqRG3r3Hp/jVeGxadla6PyZz5YPX6n+lawIVQBxWUp9EaxpnP2bf2F4nksT8unaqzXFse0dwOZY/8AgQ/eAeokroy1ZHiPTv7W0uS3jk8m5UiW3mxzFKpyrfmOfUEjvSeH9V/tbS47l4/JuATFcQk5MUqnDr+BBwe4we9Q3dXKiuV8pqlqTNR7qM81FzWxgy+FLb+2LvULK/1Cwe8Km7itZFVJyvQnKllOOCUKmqCfD/TU1db9LzUAE1FtUW33x+WJ2+8fubsHA43duMV1wNGapTZm6UX0OTs/h9pdtp2n2H2u/lsrC7N5bwyNGQhO7KZCAlTvPUk+9OPgKzfwzP4fbVNUbR5FCpbloj5IEgcbW8vd1GPmJ4P0I6vNODUe0l3F7GHY5Rfh/o0fiOXWod0dxLci7dDBbyqZAckhnjZ1yeflYc8jFdluqHdQGpOTe44wUdkWN1G6od1KGpXHYdP88bAdSOKdDIHjU+oqPdTIsruBAxnIouKxa3UFqh3UbqdwsSb6anyLimZ96M0gsSbqQmoy1IW9KB2FQbQe+STQWphNNLUCsSbqUGow1OU0yWWENTpVZCKsR1SIZaj7VaiqrH1FW4qtGMi5DV+GqUPar8IraJzzLcNXIxVWIVciFbxOWRMlSio0qQVojJjhRQKKZIUUUUAFFFFABRRRQAVxviS0Omz/AGiMf6JK3P8A0zc9voe3vx6V2VMliSaNo5UV0YYKsMg1Mo8yLpzcHc84N4pqnfSrLF8uA68qc9/Suq13wbbXNrK2lSSWd0ATGA2YyfQg5wPpXkV3darZ3Mttc4SaJtro6cg/hXNP3Nz0qEo1fhOgS/Uj0PQg9QfSpRqC+orjpri7lfeDEH7naefrzThJdH+5+RrP2iOn2R2H9oL6imnUF9a5MG7P9z8jTwl2f4k/I/40e0QeyOmOoL60xtRHrXPi1um6ygf8B/8Ar1KunTt1nb8AKPaIfszWfUh61A+pe9Vl0hj96WU/iB/Snro8f8Rc/VjS9oHIhH1E+tVZdSHdwPqavppcC/wKfqM1MlnFH91VH0FT7QtQRi/bHk+4sje4U4/OnLHdy9ECD/ab/CtvykHpS/KPSpc2UoIzItOLf66Rm9l+Uf41ft7eOBcRqFHt3p5dRTWlFS5NlqJNux3pDJVZphUZlqblpFsvWRBYTWniOe9tWQWd5GDcxkkETLgK68c5X5T0+6tXBJmk8z3pXsDimed+GfFpttC8ViTU4bnWbe+vntLS5n3yMqDKqqZ3FeDwPfFU5/ifqJ07ULmzTTJvs2k216CoZgJndFdDh+gLEY6gjk16iJM96cJKv2kb3aOf2M7WUjzi8+IGsadd6jBeR6cy2WoWUMlwsbqiwTqWZiC5wVwBnOOelZ8niabxBq+g3V0sGyz8RXFtEbdWIeJIshupyTnt17CvWRIKcJBTVSK2QnRk95af8E8+8EeP7vXvFSabJ9mnspbZ5o5o4RC4ZH2kFPOkIGOzbW56Y6+lZqv5go8wetRKSb0VjSnFxVpO5Y3Uoaq3mCjzKkstbhRuqr5lL5nvTAs76N9VfN96TzaBFvfRvqp5lL5lAWLW+k8yq2+jfQBZ300vUBakLUATF6TdUG7NKpoEycNzUqtVdc1MmapENllDVmOqsdWoqpIyky1FV2EdKpxCr0IrSKMZMuQDpWhAOlUoB0rQhFbxRyzZaiFW4xVeIVbjFbI5pMkSpBTFp9WjMWiiimIKKKKACiiigAooooAKKKKACuW8a+E4deh8+ArDqMYwsnZx/db+h7V1NFKUVJWZUJyhLmjufOF/b3Gn3clteRNDPGcMjf55FNjuMYr3jxJ4csPEFsI72MiVR+7mTh0/HuPY14x4q8Laj4dnJnQzWZPyXManafZv7p9v1NcFSi4arY9vD4uFXR6MrxzgiplnFYaTEGrEdx61gdtjbWYVMtyorDE/vThPRcTijd+1jsaQ3QrD88+tBnOOtFyeVGwbv3qM3fvWR5x70nne9BSSNVrr3qNrk1m+bR5lIrQvm4J70nnZ71R3+9KHPrSGXPN96PMPrVQMafuNKwXJ/MPrS+Z71WJoDU7Cci0JfelEvvVXPPSlDGixLkWxJThLVQMaXcadieYt+bmjzPeqmTS5NFhcxa8z3pRJ71WGacKLC5ix5nvR5lQAU9QaLBcfvNKGoCZp6xGnYXMIGpQTUgjpwiosPmIhThUwhPpThEaLBzEGDS4NWBEfSnCE+lFhcxU2mnKpq2IKesFFiXIrIp9KsIhqdIanSEVSRDkRRJVuJKdHCB2q1FEKtIzkxIUq9ClNijq7DHWkUYSZJAnStCFaghTpV2Fa2ijmmyaJasoKjjFTqK2RzyY4UtIKcKokKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFNdFdCrqGUjBBGQRTqKAOH8SfDrTdSLzaefsNyecKMxsfde34V5vq/gzXNKLNLZvNCv/AC1g+dcfhyPxFfQFFYTw8Za7HZRxtSnpuvM+YASOMUu419E6p4e0nVSWvrCCVz/y027X/wC+hg1y1/8ADHS5STZ3VzbMegbEij8OD+tc8sNNbanfDMacviVjyAMfWlya9Fn+Ft4pPkajbyDtvjZP5ZrPuPhxrkX+rFtMP9mXH8wKzdGouhusVRltI4rJowTXSTeDNfhOG0yVvdGVv5Gq7eGNaX72lXn4RE1PJJdC1Vg9pL7zEANKAfStZtC1RfvadeD/ALYt/hTTpV+v3rG6H1ib/Cps+xXPHuZoFPVavf2fcjrazj/tmf8AClFlMOsEv/fBosxqS7lQIaftPpVsWko/5Yyf98mni0l/55Sf98mgLopbM0oiPar62sp/5ZSf98mpFs5e0Mn/AHwaLEuS7mcITThF7VqpZTHpBKf+2ZqVdOuD0tp/wjb/AAqrMzcl3MjyTThAfStpdNuf+fS4/wC/Tf4VINNuv+fS4/79N/hRZi513MMW59KUW59K3Rpd2elpcH/tk3+FSLpN6TxZXP8A36b/AAo5X2Fzx7mALc+lPFufSugXRb89LC5/79GpU0DUm6WE/wCK4/nT5Jdifaw7nPLb1Klv7V0S+G9VPSxcfVl/xqdPC+qn/l2UfWRf8afs5diXWh/MjnFt6lW3FdKnhTUz1WBfrJ/9ap08I6gR80tsv/Aj/hT9lPsL6xT/AJjlxAKesI9q6lfB93/FcwD6AmpU8Gy/x36D6Qk/+zUKhU7E/WqX8xyfkil8oCuyTwcn8d85/wB2MD+pqVfB1mPv3N030Kj/ANlqvq8yXjKXc4nYoo2rXep4T00fe89/rJj+WKnTw1pKdLXP+9I5/rVLDTIeNp9meeYWlyg6kD616THommJ0sLY/70Yb+dWYrK1i/wBVbQJ/uxgVSwz7kPHR6I8xjKucJ8x9F5q3Fa3L/ctLlh7RN/hXpYAAwOlFUsN5kPGvojgY9NviMi0m/FcfzqzHpd+f+XVx9SB/Wu1oq1h49zN4uT6HKxaTfd4QPq4q3Hpd0OoQf8CrfoqlSijN15MyY9PnHUp+dWY7WRepWrtFWoJEOo2QrER1IqQKRTqKdibiYpaKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopsrrHG8jnCqCxPoBXN+FPHGh+LFik0F9QubeVC8dy+mXUMDgHBxK8aoTnjAOeD6UAdNRRRQAUUUjHapJ6AZoAWiub8H+MdP8VeCbbxTp8F9Hp88ckixyQF58I7Kf3ce4scocBck8d+K37WdLq1huIxIqSoJFEsbRuARkblYBlPqCAR3FAEtFFFABRRRQAUUV5P4X8ea7rfj7XdIkltbey03VWsUSLQru4MsYAOXuUk8qJu3zD3xQB6xRXlll8Z9H1K0t3ttP1ayF/bXsthc3cETxyvaqxkXak27I25wdoPTcM1y/j34zT/8ACtL6fwt9t/t6DTbK/nv0tIkgtBO6bQ6SSPyykgKvmYzyeCQAe90V5m3xo8LR+MU8Nl7l7w3y6Y0ymLYLg8bdm/zcbvlLhNueM1Usfjjol7p8N9DoPicWk97Fp8Mz2caJNNI7oFRzJtbBQ5weMj3AAPV6K80034v6PqNzaWy6dq9nJdXlxpySXMURSO6hXLRuElJPGMEZU5+8OcZ2m/GzSBpvh77bFdXF9q1mbxGVLewjKiQx4/f3O3dkfcWRz370AeuUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFNlkSGJ5JXVI0BZnY4CgdST2FADqKzIvEGiyrpxi1fTnGo5+xFblD9qxyfK5+fHfbmtOgAooooAKKKZPMlvBJNK22ONS7HGcADJoAfRWNpXifRdU8MxeIrTUIRokkZmF5NmFAgJBZt4G0ZB64rWgmiuII5reRJYZFDpIjBlZSMggjqCKAH0UUUAFFFeT/HLxJ4s0PVPCNr4Jlj+13txcGS1eJHF0sUYk8rJBK7gCAVIOT1oA9YorwHwN8Zr/UND1jVJ/IvJLjXJLTTLC5MkUwh8pXESLBbyvIyk4OV75LVV8R/Fu68ReEIrzSl1HSm1Lw5qV4EiukAglgZkzu8oSFgVJDK6D1U0AfRFFed6z40m8IfCbRNemtW1OeSCyidZLgoXaUIpYuVY5yc9Oa4zxD8Rr3VNd0KzcPotxpfiyPTtRFrfGSCaPyXY5fam5eOVZRjFAHu9FeCaz8bb+80rX7XSNPtoL2PRZ9SsdSt55pIH8ttrFfOto9+OSCoZGIC5HJF8fF/WdN0/wAP2E3hqbWdfutFi1aVbJ5pBLG2FBTy7c/O3JIIVF6bzxQB7ZRVfTrn7bp9rdGGaDz4ll8qZSkke4A7WU9CM4I9asUARXcZmtZolIDOjKM9MkV87zfDnxN4Z+Ces6HNYLfXS6dJArWGtXt15zNKHASyaMRqfdeeD/eNfRtFAHz3afCDxBd6VfzodJ0uO+l064OhxSSC1uFgX94twfLXDSE5bCHkc7utaVj8HdT+0aMdQbRm0231251ObSgWktre3ljCi3iBjAYA5yCFXngevuVFAHzBrXwn8SaRo/grSLGaR9UuGu9G1C5slklhj02aQyHc5UbQoJABxksQM16Vpfw4n0nx3e6kul6Dq+mytbCxlvpWW50qOJAmyBfKdSBgEYZD6nvXqtcr4euJ9S8beJrrzpDY2XkaZDGGOwyKpllfHr++RM/9MyPWgDyPQvgdrelaHpVtDPosV7Hoep6XfywvIv2l7jzPJJPlgsq7lzu5GOAcCl8RfBjxPd6Jf6fY3Wit9v0DTdKlea4lTyZbVoyzKBE29W2HBO089K+haKAPB734Manda1NqEjaM8kniW21TzGLl/sSRlZoc7Or8fLnaQOTXoXwl8J3vgzw7e6XfSWrRtqNxcWqWzMUigdsogBAxjngDFdtRQAUUUUAFcxZ+BNBsdcutXsotQtr26uftdx5Op3SRTS/3niEgjbp0K47Yrp6KAPM/Afwe0Lw1pUUOol9Xv0S5hF1K8qKkc7MXWOLzGWMlW2llwT+NWI/hn4B1zTGW300y2JhXTJFgvbiNJUt5Cio4Vx5mxkIDNk/L1rq/GOsHQPCuq6oiGSW2t3eKMDJkkxhEHuzFR+NO8I6QNA8L6XpW7e9rbpHJJ/z0cD53+pbJ/GgClF4J0ODXJdXtIby0vZpluJvsuoXEEU0i4w0kSOI3PHO5TnvmoYfh94Yh0LT9Gj0zGm6fejULaH7RL+7nDFw+7dk/MxOCSOeldVRQByUXw68LRTQyx6XiSG/m1ND9ol4uZRiR/vdx26DsBVeT4YeFJdHtNJksbxtJtkWOOwOpXX2cqrlxui8zY/zHOWBPT0FdrRQAgAUAKAAOAB2paKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqGv28t3oWo29uu+aa2kjRcgZYqQBk+9X6KAPnfQfhf4qt4vhal/NqLxaWLldQg+0WyDTg8e0GJ4wrsTnrucjA6Vy41Dxmvwu8dazf8AiXUnXQEGiWF1b3si/aXS7BkuSQ2S21kQN6ZHrX1hRQB4LDoHxDmttSntDrcOiz6pYzx6ZNq4e+e0WM/aRHP5p8vexUhfMHAPK95dN8K/EK5uPDkOq3esRaSNS1F7iNNXK3FvZPGBbRzSpJulcMDyC5Gete60UAfMOo2fxI0nT/AelXOu6lB4j8QW9xo97BLfGVoAs/mC6UqxG9YTguDnGMnOa9DtvD/iWHxXrq6xB4g1Wyk2ppFzbavstoIRGV2zwmZC75+8xSTdnNd9461abRPCWp31moe9WLy7VD/HO5CRL+Lso/GtPSbaSy0uztZ55LmWCFInmkJLSFVALEnqTjP40AfPWgeBPiJoPhfT7HSv7TtnPhu7tri3XVV2RXpdjD5Y8zajYI+ZMD1PWrfirQPiobTXbfSv7ZlkvbDSxaTQ6siC2miCi5B3SqVZsMSVBDdzzX0JRQB4XN4U8fzeJZLtrrWxav4rdyqayyx/2Qy4OEEuAM9ABvXsBXoHwjsfEWm+ETaeLnuXv4rucRNc3AnkMG8mPc4ZiflPc59a7SigAqrdadZXd1a3V1Z209zaMzW8skSs8JYYJQkZUkcHHarVFAGHN4Q8NTwSQz+HtHkhkuDduj2URVpz1lIK8v8A7XWlTwl4bS3jgTw/pCwRxSQJGLKMKschy6AbcBWJJI6HPNbdFAHNeNPBml+LvDC6BfiW305XidUtdibRGwKqAVI28AYx0qp4JsNA1PQYZ7Lw5pVnYW9/PJYxxW0YUFJGjW4QBQFZguQRzgjmtDx/qk2jeD9Uu7Ij7eYvItATjNxIRHEP++3WtHw/pcOiaFp2l2uTBZW8duhI5IRQuT78UAUbHwd4Z0+WSSw8OaNaySI8btDYxIWR/vKSF5B7jvUcvgjwpNYwWU3hjQ5LOAs0MDafEY4y3JKrtwM98V0NFADIIYreCOG3jSKGNQiRooVVUDAAA6ACn0UUAFFFFABRRRQBDfXUNjZXF3cuEggjaWRj/CqjJP5Cud+GlpPb+DLCa9UrfX+/UblT1WSdzKy/8B37fooqD4n/AOleH7fRFPz65eRacQOpiY7p/wDyCktdeBgYHSgAooooAKKKKACiiigAooooA5Dxsf7R13wvoIJ23F5/aFwvrDa4cf8AkZrcfia6+uQ8Pj+0/H3iPVDzFYJFpEB/2gPOmI+pkjU+8XtXX0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAch4pH9qeMfDOjKQYoJH1e5H+zENkSn6yyKw/65Guvrj/BhXVPEnifX/vI9yNLtmx/yytsh8f9tnnH/ARXYUAFFFFABRRRQAUUUUAFFFFAHIeKv+Jn4w8L6MOY4pJNXuR/swgLGD9ZZUYf9czXX1yHhI/2n4u8U6z96OOaPSbc542QAtIR6fvZZFPr5Y9K6+gAooooAKKKKACiiigAoorMu9d021cpJdI8i8FIgZGH1C5x+NJtLcaTeiMO4xqnxQtYvvQ6Hp7XDenn3DFE/ERxTfhIPWuvry/wT4jef+3NZgsmkbVdQkkieWTYPIjAhixjJwVj34wOXNbcuu6pKeJbeFfSOLLfmxI/Ss5VoI2jh5y1sdrTXkSNd0jKo9WOK8/udRuZmxPqM/8AurJs/wDQcVTMcDNuaJpW/vOpY/m1Q8R2RrHBye7O9l1zS4jh7+3J9FcMfyFVn8TaYPuyTP8A7sD/AOFcULlAdkYQN/dLjP5DNTIt3J9y2m/CByD+JAFT7ab2Rp9Ugt2dX/wlFjn/AFd3j18k1ND4k0yRgrTtCT/z2jZB+ZGK5MWWpkZFnKR9EH83qGUz27BLqBkLcAMu3PsM8H8DR7Wot0H1Wm9E/wATttQ12yspPLZnmmwDshXcQD0yeg/E1j6j40hsLG5vJ7GZLe3jaaRndRhVBJPGewrnol+ZYbOEhnbhVXBJ9gf59BWsnhy7lXM91HHnqgVn/XK/yo9pUlsJ4enBe+zN+H2rXGm+E7Nbuw/025L3t1++586ZzK45HYuR9AK6eLxTDuxPZ3Ma/wB5drj9Dn9Kz/8AhGjj/j9bP+4f/iqim8PXkaloLpJj/cKlD+ZLD+VPmqi9nQelzrrG+tr+LzLSZZFHBx1U+hHUH61ZJAGSQB715rbSSw3IdHeC5GVDrwT2KkdOPT8RUU7Cdx5glunY8eaxct9ByT+Ap+3e1tRPBu+j0PSHvbWM4e5gU+8gFSRTRSjMUiOP9lga83SynC5TS2C+0TD9NtQuiwOGmtDbvn5W2mNs+xIX9DR7aX8ofVE9pHqNB4rhbXW9RigMUUySqeA84JeP/wCK/H9elU724e5f/TLiadv7hY4/75HH6U3iI9EQsJNuzO3udY062YrNe26uP4d4LfkOaqN4m04H5DcSf7sD/wBRXFRSqG8u2jTcP4E+Zh/wFc1cjttRk/1VrMw94wn/AKGwqfazeyNfqsI/EzpT4ntv4bW8b6Io/m1KPEsB/wCXO9/75T/4qsFdM1Q/8sSv+86D+WamGlan/dT/AL+j/wCJo56hLo0u5sjxHB/z53v/AHyv/wAVTx4ht+9teD/tnn+RrF/szUx/Cn4Sj/4mgWGqDrET9JE/wp88xeyp9zcHiCz7pdD/ALd3/wAKeNesD1kmX6wSD+lYP2XVF/5d5T9DGf8A2YUoh1UDm1kH1WM/ykp88+xPsYd/xOhGtacet0i/7wK/zqRNUsH+7e25/wC2grmwNQX70D/9+T/RjQXuf4rV2/7Yyf8AxJp+0l2F7GPRnVpcQv8Acmjb6MDUoIPQ5rjgRn97axj/AHlI/moq5ayW4IAiQH/ZZf8AGqU32JdG3U6WiqlqyHBUMPxyKt1adzFqwUUUUxBRRRQAUUUUAFFUJ9Vto5GiiL3EwODHAu8g+56D8SKie6vpFHlxQW2e8p8xh/wFcD/x6gHpualYXjTxDB4a8N6lqMjxme3t3khgLANNJj5EA7ktgfjTmt2l/wCPq7up/wDZD+Uo/BMEj6k1yvim2gudd8OaHaQRRLLdf2ldeWgG6G2wy59czNB19DTsyXOJu+EFi0PwppmnItzdTW8CrLIsLDzZcZd8kAfMxY/jWm2o3j/6mwC+88wX9FDU4knqaSnyke17IiM+pv1ltIh6LGzn8yR/KmFLx/v6jOPZERf/AGU1YJppkUdSKfIiXVkVzaM337y9Y/8AXcr/ACxSf2fCfvNcN9biQ/8As1PlvIIv9ZIi/U4qnJr2mx5DXtsMesq/40cqF7ST2ZZ/s+2/uufrKx/rR/Z9t/dcfSRv8aoHxNpQ/wCX2A/Rwab/AMJRpX/Pyp+isf6UWiNe0ff8TR/s+DOQZx9LiQf+zVQ8QTQaHoWo6pNcXghsreS4YC5fkKpOOvU4xTP+Eq0v/nuf+/bf4UybxFo9xE0U8sckTDDJJGSp+oIotEf7xdH+JH4K0S70fwrptpcX90t4I/NuirAhp3JeU8g9XZj+NbgS+X7mpSn/AH4kP8gKzR4m0s/8vsA+rYp6+IdNbpe2v/f1f8aOVCc5rf8AI0RNqif8t7SQf7ULL+oanrqF+n+ssoZB6xT8/kVH86ox6xZSH5LmBvpKp/rVlLyJ/usp+hzRyIPbPqWY9WUnE1pdxH3QOP8Ax0mpoNVsZpBGlzGJT0jc7H/75ODVQTIe9EqRTxlJVSRD1VwCD+FLkZSrIvXeoWdmD9ru4IMcnzJAv86xL/xNnKaZCZCf+W0oKoPoOp/T61Xn8O2LeY1r5lm8n3jbtgH/AICcr+lZkmhahAWPni9jHQA+U/5Dg/mKxqKp9k66EqEn77Irq4mun/025knY/wDLPOF/BBx+eawfGGoy6P4Yvp7ONI7ny/KtlY7d0zkJGAB/tMtbqSxxsYRGbeY/8s3Xa319/qKyL6azufEfhXR5YlhlFw2o3UzkN5qwLhPmPT99JEQD/d4rBUrv3mehNqELxRd0LQ5rDSLDT7OC4aC2gSFDsEQwoABO7ntW1D4fuXH71reIH6yn9cV09LVqCRzvES2WhiweHrZBiWWeT2DBB/47irkWlWEQwtpEfdxuP5mr1FVYyc5PdjI0SNdsaKi+ijAp1LRQSFMkRJEKSKroeCrDINPooArW9la2zs8EEcbt1Krg1ZopOnegG77i0mab5iDq6j8aTzov+eif99CgDM1TRIr2Qyxv5Mp+8du5W9yPX3q1punwWEW2IFpD96RvvN/gParQljPSRfzFKHQ9GX86LLcpzk1yt6DqayhlKsAykYIIyDS5B96Wgk5u/wDDrNd77F0ihf76sT8n0A6j2yKvWWg2VuMyIZ37mTkf989K1qKSir3LdWbVrjYo0iQJEiog6KowBT6KKozAUtApaBAKWilFMApRSUopiFFOFIKcKYhRTsUlLTJEVVByAAfpTqSlpiCiiigAooooAKx9QP2nUzZzMwtlgEpRTt8wliME+gwOPfmtisfXl8mW0vR92NjHIf8AYfHP4MF/WgHe2hKm2OMRwoscY4CoMAUlRvNGiFmcAAZJqml5Ndj/AIl1u84PAk+7H9dx6/hmtNEcqvLY0CQOprhtI1Kyl8XeI9bu54o4bcppFszsBkRDfKR9ZJCh/wCuVbXiGOa1siLq7Z7yYFYbe3OwA/3i3XAz147CuX0fQrTTLVoo4x87O7kkkkuxZiSeTksTknvXPVxCg7JXOyhg5VFeTsjo5/FMR4s7Web/AGmHlr/49g/kDWdceIdTk+4bW3HoAZT+fyj9KxC/lloXfPl8A5+8vY/570yOYTOUgR5n/uxKXP5Ct4tSXMdsMDSjq9fU0J9Sv5lw99Of90Kv8hVKRWk/1s08n+/KzfpmrQ0vVWXcunT7fVsL/MipW0DWBGXeO3jUDPzS5P6A0XiapUIbWMwWsAP+pjz6lQakVEX7qqPoK2ofCeoOm6S9t0+YLhULdT9RU8nhCRIndtRJKnGFhx/Wjnj0G69NdTk9M1GLUDdiJXRrW4a2kV+oZcHP0III9jV2l0nwrFB8QNRsZb25EeoWMd/GyhRudD5Uvbspt/zrpf8AhErMNhru8OBz8yj/ANlpc6JWJh1OZpM11Vx4RsYpQvn3hUrn/WD/AAqX/hD9OEcjGW7O3n/WD/Cj2iD61A5DI9aa6g9ga7OLwbpsiBvNu+f+mo/wqC38IWTRyEzXe9cEfOP8PUGnGrZ3QpYim1ZnHtsxhoYj9VFM8u3P/LvCPooFdfF4Ss50ffdXS7eSAV6flUTeCrUb9l9djBxg7T/SulYqm17yOduPRnLriP8A1TSxf9c5WX+RqSw1i5eIS2epSyxEkBt4kGQcHkg9wRXQTeCvlzDqLc9A8Wf61yXhzwre2mq+IdKju4GFrcLdRBgy5iuAXz3x+8Ew/wCA1XtqDe34Gb5XubkPiHVoj/roZV9JI8H8wR/KtK28YSLgXdi/u0Lhx+uD+WazZfDOrxReYIopU6/u5R/XFVW0vU0BL2Fxgf3V3fyzRajLZ/18yXRpvodhHrGj6uggleJy3SKZdrZ9gcH8RVS/0AofP03y52CFDFPyxXOcK/X8Dn6iuMnKxny7uMxn+7Mu39DVi0vbi1bdZXckX+zncp/A8fliolhlLWLuKMKlJ3pyNaw8Uy6ZcfZriGURRnbJBJ9+L/d/w6HsRXeWd1DeWyXFrIskLjKsO9ed3upw6rb+Vq9qBOoxHd24yUPuDzj2yaqeGdXm0S7DSljZOcTKM4HbeB+vuKmWGUo3grNdO/oHtJ83vo9WopqMrorIQysMgg5BFOrgNAopKrSXJYYt8EH+M9Pw9aaVxN2LDuqKWdgqjuTVZ7on/UxnH95+B+XX+VVZ5YoFMtxJyP4mPf0H+AqnLd3MpItoAqf89JjtH4Dr+eKJOMPiZKbl8KNFnkYfPKeeyDaP8f1qJo4h80gX6uc/zqgEuSQXuomJ7eWcfluq5aXSJcLDdRQ7jgCWNOMnoCO2e3NSq0G7Ifs5dWKHtf4TD+GKdvg/2PyrVqKWeGIgSyxoT0DMBV8wuQz99t3MQ+uKN1merW/5itCKeKUkRSI5HUKwOKlo5h8pmqlq33VhP0xUgt4eoRR9KttFG33kQ/UUwW8GeIYv++RSuFvMgECf7Q+jkf1p3kjs8o/7aN/jUxt4j/yzT8qb9khP8GPoxFAWfcaIyOksv/fWaUBx/wAtX/T/AApfskXbzB9JG/xo+yJ2kmH/AAM0AGJP+ez/AJL/AIVIhcdWz+FM+y+k8w/Ef4U9IWH/AC2c/UD/AApgSg5p9NVcd806gQU4U0U4UxCinCkFKKYmKKdSClpiClFJSimAUUUUCCiiigApk8Uc8LxTKHjdSrKehBp9FAGVDoFhGwZ45JypyonkaRR6cE4/HGa0Z5Y7eCSaVgkUal2J6AAZJqSsLxjIRpkcAOBPKqt/ujLEfjtA/Gpk+VNlQjzSUTl7q6e8uZb65BV5MBExyifwr9ecn3J9qda2s17KUjj8xwMkE4SP/ePc+3/66iSN7i7jijxvZgi57E8kn6DmustrT7LEsdo2VTnIYFie5P1rlpw5vekejVqKlFRjuZlp4espJkbU1F1Ov3Q4wi/Re4+pNa01slsgFsiRR9NqjAB7cCnsRIMSYRx/EOB/9apEJYGGbrjg+tdFjilOUneTJFIuLXjjK4x6GqxTzISp64xSRS/ZRukYCNjgk/3qq3OtQLKVhjZ5R1UZJ/IAkfiBTurakWdyzZEm3dG+8rDP4Gp5U3RzJ3zmsRry/eVpIYFi3DnfgZ9+pP6Uv2jU2JPmwqT/AMC/9lFZOrFdS+RmR4kY2Gt+F9Vxxb332Cc/9MrlfLH/AJGEFdXdDy7oZHykZ+vY1xnjW01S/wDC+qW8IWS5aEvAU5KzJ88Z24HR1U9T06Vr2PizTNZ0Kw1CGVVNzDHcIhdc4dQcdfQ1cakZLRkuLTOguU326PnJQ4Jp0JBUb+QRtb6Vkxa7AIyqwXD54ysZYH8Rmmrqs+CIrGQjsScf+hYo9pFdR8jNW0YwyvbyHkdD6j1qRVMdxzyj5H5/5/WsKa9vp2Qi2CMnRjgH6cMad9s1M4yIf+/v/wBhUurBdQ5GabA21zu/hNDjY/HKkYHuP8R/KsuW51CVcM8AH1z/AOyimLLfPHtE8JUH+6Tg0nWh3Gos3IwJUKDqRuX6jg/0rktQAsPiHo12/wAsOqW82ly/9dFHnRH8Ak4/4F+eqsuoAqRdQgr/ANMv/r1y3xI+3N4anvRcQvc6Y8epRIsWGYwsHKjn+JQy/wDAqFWgDgz0K3zGWglGQePrTWQwMN3KnjNYqXV9dQxzR3cEkbqHRhHwQRkEc09rjUmXaZ4CPdKft4dxcjNW6UnYxAPY56Gs+fRNLuQGext8k53KgU/mOagNxqBUoZICMYxnH9KEn1FF+9DjHOW/+xpe2h3GoyWxRvvC2nxzZjE8KsMDbKTg/wDAs1kf2DBaXQF+881sx4O4BfocAcfjXRyS38se15oAv4nH8qhkgupk2SXULJ6eWf8A4qq+tW+0/wASrSNu33RIxiTMQ6xjqv8Au+3tTn1C2TjzAZP7g+9+I7fjWElkRGqSXcxVRtCgjGPTnNMisrMFsb2x1yxA/IcVk68egKL6mnc38JOLmWNV7RBsk/X1+n86ha8mnyLaEqOzygqPy6n9KqwvFHKyW8MaKByQuM08XO6XY3GR2qXiHtFWF7NPVixrFHKHmk82cfxt/D9B2/znNOuQZxtT7uetUzaSCQ7eQe+avxxrEm92OEHOawbu7ssAgiwkQ/eMOCew9acqjDRocIhBmkPb292P+HtTB5nyqmBczHjP8CjufoP1PvUo2LECCfIjyUHUse7H1JreEeVXIbuTz3LyglmMMI98Mfqe34VXQnB8iNUB/icdffHU/jUczMqebKPm/hTsP/r0y2nM8LtJlecUpVG9gUe5Lw8i/wCkN5inKkADB9uK0UvGUATRk+rJyPy6/wA6yI44tylXJwetTszJIzknb2FSpyRVjVF5bnrKqn0f5f51KsiP911P0OayIrgS5C4J9DSsseMvCh/AVoqr7CsjYp1ZCQwsAfKQfhSMkKgFoVx9KpVPILGwSB1NNMiD7zqPqaytsGARCnP+yKmVIwoKxIP+Ainz+QrF03MA6zRf99igXVv/AM94v++xVddo/hAp4IxxT5mKxMLq3z/r4/8AvoU77TB/z2j/AO+hUJIA5ppYZxgU+ZhoWVnhPSWM/wDAhUiuh6Mp/GqZVSRlF/KkaOEH5ok/75FPmFY0B0p1ZwghJ4iT8BUyQR5wAR9GIqlIlouilqFIwOjP/wB9E1MOlWSFKKSgUwFooooEFFFFABRRRQAVyvjJ83mnx9gsj/8AoI/qa6quT8YjGpWDdjFKP1Ssq3wM3w/8RGf4cjWXVWZmI2I5GPXIX+QNdT5SE53En/armfC5/wCJlKPWNj+T/wD166SaaOIgOxLnoqjk/hUQajG7NcQm6g9ouOG/PmnFRsJYAbeeKoSu0hzIXijH8IbBP1I/lVOKTzb1I7UYwQWI9O+aweMjzqMVcj2TtdlYZvA9zcsxjBIWNTjODzn2yOn55qZpVgjUxhI4j2UY5qOJfst1NaN90ktHnuO4/r+J9DQ+JU2SrtXPHtUVG+ZpglpoMnMjt5sbEqB0BqH7a2djcE8ZFYniPxhovhCGCbWrwWttPKIEd0ZgWIJx8oOBgHk4FX9F1nSNY1DUraymWW6091S5XawEZZdw5IweO4zU2e47l+zcRyESSfMR0rA8Bymz07UNHB50u/mt0z2iY+bEPwjlQfhV/V9XsdLLSXUd1IFhlnzDbu67Y1LMC4GxCQONxGTwK5e88Y6Rp3hGXxkllOtjcwxXUgSNfPdW2qu75sEgEDrQk2hXO4luZo8sxAX2FVV1GbIJPy1ajKXdlG+CFdQRnqM1i65NBpdlc3Mrlo7eJpXCD5sKCSBnvxSSGbLztNDwx5GKZFKbdFi+ZuOtZPhjWIte0Gx1OwSVba7iEsaygBwD6gEjP41aivFafDq3B60WewE/2u3j3bty568VOCrIkkTkL7VgeOda07w14dvda1GO4ltrXYXS3UM53OqDAJA6sO9Zeg/EXw9qLpaW87wxvpY1Y3NwUjhii83yyrsW+Vw2QRjHHWnytq6Fc7Vn2vuGeaqTwreysWZWQjaynkEVinxXo/2GO6stQs9RgmuUtN1reQEIz9MlnAP+6CWPYGofBPiCLXNN1W9eEWUVjfT2bl5dwIiON5OBjPXHb1os9wuTfDm7aHw9FpsxZpdLlk05iTk7Ym2oT9Y9jfjXXpgb9p3E849K4W18S+D7K81C+tdf0gtdyJNcN9vj2htiorfe4yqqPfFdBceKNDW9TTBrGmLqcpVRaG6jEzFgCoCZ3cggjjnNDTuCZqL5e4yMcEe9RXd3GIwA2A1cVoXxC8Ma7bXkseqWtqlrdm0b7VcRJvYH5WX5jlWwdp74PFWZvFGhz3My/wBpWUVtbpERdveQeVL5mSu3EhYZ5xuAz/Dmjla3C508atJAyoeW70qRSRHJfAx61WtNTtZbacWF1b3UlvKYZRFIH8px1VsHhh6Hmp8+ZA7PnpmkMWSVwFIOcnFSwlYY2Zwfm7VSsXfy324JHQGrc3mSQocfN0xQAqSrIx8sYPeokhkLM2CTnrSWw8pyZDtJGOatQJMI2wQxPIoAZFMQSCxyOtXT+8aJDyPvn6Dp+v8AKq9rGVb96o3t1p8+4xTeWcPKywIR2yQufwJJ/CrgrsT2Jo/3il+8/Q+kQ6f99HJ+lK2HmwfuRfq3/wBYfz9qlJUPIVAWNP3aj0VeMfnmqsj7LUMxxn52H1rWo7KxK1foQ3N0rzBQm4DjNFyUaEImAQc1FEwdgwXvUhhBYAHnrWRQ6FCUUdKsTKBbnc1ZrSyC4Cj7mcVdkIZNjHBpgN0+LEv3verM5DSqMnj9aYirbRbvvMelPg/enewpgSK2JVJOBjpU0oVlBY49KiAVsM3anuFkUYPAqkIZtyRt6AYqzx5ZAwTVcCNQAWqdAFG7PFUIjjcsxz0q0oGzioxsPIFOU8c9KoBwBA5pgUs+RUpHFCbvwqhDvuqAaRhuGaccdTQCAOKBDoxgVMvWolPFPU81SEydakqNakFaIgKUUlKKoAooooEFFFFABRRRQAVznjKLK2M3dZGT81z/AOy10dY/iyAy6HO6j5oCsw+inLf+O5FRUV4tGlJ8s0zldJn+zaqrkcfvEx9VDfzWt6GZFg8xiDI3LN6muYdzFMJAM7dsgHrtPP5jiunt9KhIDec8kJGVUccdua86rTqVIxUD0K1k+ZlTdPqMpig+VAfmc9B/9f2q9bFLZTDYoHwfnlY8E/1/lSGXzgYLNRHbDguvGfYf4/8A66bczLbw7VwoA4Arn5o0F7ru+/8AkZay3I7mGS+fYxTzkXejoNuCCODkn1/n1yaqxyGfMMw2XCfeX1HqK0bctbQjI3XU3O0/wjtn2/rVeeI3koim2pcgZjlTjOOx/wA//X6k00oTfvf1oZtdVscH8R/A/wDwlkmgw4tmsrW/W4u452I8yHYysq4Byfm74+teeWHwq13TNO1nT7a/0fUIrrUIJIvt8YkZraNWUKS8TqkgG0A7HHBr3V5XizDejy5Oz/wn/D+X8qrSWbxYZQWPXinzSh7rJcU9Tx3S/hTr1lpuhxSXmnyf2cNUQjzXOEuYdkQX92Bwck8ADsD0roNU8CX9/wDBuPwmk1omqrZQW3mM7CHcjISchc4+U44r0guUVcgg9hUCuZLgfKRSdST1DlR43c/CvXbi31cR3Omab9tv7W6GmWjlrVlhQq6szRYJckMcxsMqMhu1a9+EOrpbWMcf2C6t4Uuk+xXt6ZooWlA2yRlbdFypyQvljHZvT2uS4JuSoTCg4BqO0SZ5HG7c3pnpT9rJC5UUPhzoU/h7wZpOl3rRSXNrbrFI0RJQkDnBIBx+FXordDcsOflPTFX8Mke2eaOMn/axSmSAqAlzDu/3xWbd9SrHJePfDB8W+Fb/AEc3Zs/tGz995fmbdsiv93Iznbjr3rlx8LtninxHq+ga1No8uq2bQIkEGfsztIkjOp3dCUPygD75wRxXqtvC+xt0iOD/AHTSwQPEXIHX9aam4qyE43PILL4PXMD3LS62ZpLjUbTUWcwO3MGcjLysx3Z6ljj0NdZ4d8H/ANkeH9d0k3/m/wBqXNzc+Z5W3y/O/hxuOceuRn2ruY0OSzA7jwagmt8IzqCG7U3OT3BRSPIv+FNtHYCE60GI0FtEyLT1l3+b9/8ADb+tWr34U6jqN1p7XXiq4ks7GW0mgt5IXKxGAAEKolCfNzyULDP3jzn0KR3R8Z/OryGR4GCnpyM0/aS7i5UeY6r8KnksLuyk1aGXSptdGt+TJY7mySd8TN5mGUg4ztGOc5qS8+G8d8/iOPTr+2sLXWbW3szAtiGW3iiBBCDcACQeDj5euDxj0+1UmBjOwI71X+0WyybU6+wpe0kPlRgfD/wsvgzQf7G+2pdWqSu9ufIEbojHO1yDh2yT82Bn0rcnmWOVoxjaeMU9tssu48AdTUNwYJHDKQxFS3d3Y9iztitoVZVGW55qZ2j/AHbEgHFRqytbgyAE9qqMc4fJOKAGXkTzznaOvQ1etGW1hCM+5ge1V45B5gO/APY1LO8EZDPglj60AWolEkvmgn6VJZoHlsyf+erPj1+VqbbNG0YKDA6U6yOJLL08wqf++WrWl8QpDWO6wz3def8AgX/66huRumYYO3HPpUzDFkB/cwD+B5/lVe8kf7UI1HykU6m5MSAXIUhEQbRUsJZrncenQVWlaOB+eW9BVq1niJU1BQeUiTglwcHpSpEXmyx96Sa3PnblI2k5qRiwkBSmBZnAWHpnHSnQfNb8DBxVe88xtoTOMVMNyWyg9T1pgRRAK+GcZ9KtLGfKIXuaoCJy+4DjPWr6ybVAAyaoRB5RL+lWRgKEzTHUueKfDG+fm6VSEO3bPlFSMcRg0hTodvNO2FuCMCqAYrmrAOcc4qNI8U8Kc+1MQ849aUDimFOpp4zs9DTEL+NSp0qsoI9TVlM4HFNCZNHnvUtRrUlaogKUUlKKoAooooEFFFFABRRRQAUjKGUqwBBGCD3paKAPNri3ayklt2yTaPsye6Y4P4qQfrW/pFwJNBmhzhrdGjPP8OMqfyx+Ro8X2pjuYL1R+7cCGT2PJU/qR+VY2lXAtL4K4/cyAQyD1Q/dP4E4+hJrjtyycD00/a0r9Ub7yrDAAuBgVDboGZLm4BK5zFH3c+v0qwmkjzczzGSIdExjP1PenPKhupX4IT92pHTjr+pI/CuBUXSXtKny/wAzPmT0QLuDvJJgO5yfb0FVN5k1CBU+8HB/Dv8ApmnSSlmJ7U3TkYRSzD/Wyv5SN6DuR+v5VhTbqVU29tWU9Il67kinDIYvNVcjdnGD3wazo7KZIy9i+6MHBhcdPb2/Dj2rSlCwxBFGAoxioLCba11Kfuqq/ieeK7oV3OpyS2MnGyujPllAYLc28iEdwM/p1/ShXtnJxMm49icEfhWqfNljPmuOf4doKj8xUcNvbTs0U0KBwM/JkAj6dvpTj7ObtFiaaMtLRVkLGRSv1pCInPk2nzNIQHZPT0z6np7da0ZdPsI5NiWvmOOSFwNv1NW7IQo5RYfLkxkZOcj2NaRhBSs3qLW1yCLSrK2g3yxopAyxX5QD7YxULx2R6Wk7D1z/AImrt789zBGegBcj34A/mac4AGMVNavKDtHoOMU9zPj07Tbptojw4Gdrxrn9RTm0KMf6qaSMezMP0VgKFk26jAB/eIP5GtC+mMFuSgBkYhVz6n/OaqjVVSDlNbClHldkZo0q7Q4S8Yjtux/VSf1prWuooekEoHYDafzz/Sra2q7d8hZpDzuLHP8A9arFnIxeSJ2LFcEE9cH/APVShOFR8trA01qYk8U2AZrAkjn5Dn9cCmrdQqrI0cseeCNucflmtlZZJ3dkcrGrFVAxzjgmlil3T+TPtkDAlSVHbsaX7uUuVBZ2MItA1u8Mdym9uznB/KoLfT5Nw3/mDxXRXlrZBP30Iw3AVQcn8BVFdL0+UgW8kkEn90EoT+HBNU6SvZPUXmVprYvDLH93d0NZUVrLbybXXP0roH0u8QfubosB/ex/UE/qKqzfbrc5nt0kA53KpXH5bh+ZFS6UkF0yJY3VQCvB5+lTTFY7fBXJb0qNb+CRcssiD+8BvX/vpcgfjTyi3KhoZUlT1Vs1m01uMzvIecfKQPrRc2irCglc5XoauNE8cyhFJBqS9tzLH0yRzRcAsGVEVEYEetSOxjt3f/nhKJD9AwY/pkVQsFkadQVIANagA89kYZWRc/lwf0Iq6ekiZbEs0eWuYvVmwfXdz/WqkqmUQyrxkc+tTwSFo4txyygwPn+8vQ/iDmmSFliuEX7y/Mv0P+SK0qLqJbtGc1m8shBB+tXYrFI0UlsY/WqthcyTEoTz61bngkdBhs4rModcYWMbTkgVHZlt/wAw5IpqRttCZ59auxx+WVCDfK3AH+e1NASEMO4wB3pEZT/qw8hP9wEj8+lXIrNBhpsSv7j5R9BVkcdOlaql3FcoJDK3Hk7R/tMP6Zp4tpz0MKD6Fv8ACropa0VNCuVBayH79wR/uIB/PNPFpxzPMf8AvkfyFWKUVXKhXZXFnH3aU/8AAzTvscXrL/39b/Gp6WnyoLsg+xxesv8A38b/ABo+yJ2eUf8AAzViiiyFdkAtfSaUfiP8KBan/n4l/Jf8KsClFPlQrkAt5R0nB/3kz/LFPSKYdZIz/wAAI/rUwpwpqKE2JGG/iA/A0+kFLVEhSikpRTAKKKKBBRRRQAUUUUAFFFFAEF7bR3lpLbzDMci7T7e/1rzfUHjspktb6aKO683yFVyF85tpbCg9cqCcf4V6bLIkUbySuqRoCzMxwFA6knsK8wg0+fxZfP42aPEEaGHSbcr8zWvO6c998h5X0QAcFmrGrDmV1ujow9XklbozqPDuofaIPssr5mRfkY9XX1+o6GltAPIWNxh0+VgexrnA7ROlzbSbcEOGHOD6+4PQj0rpLWSPVozIh8i7TAkXqD6H3Hof/wBVcdaDrRXLujqnDkfMtmQ3QLusMP32OBV0KsUixp9yBQv4nkn+X51Jb2q2SSTSN5kmDzjHHoKbGm2PL8u53N9TXN7J0YO/xMjm5npsUdQuxtIzUsURjtraFgQ8jebIPYdB/wCg/lSJbJcX4BHyR/O39B/n0qdG8+Z5/wCE8L/ujp/U1NOLjB1Hu9F+o29bIkuHCJ1qLTCCZ7hz8qjbn9T/AEqvqLsEJ5wKueT9n0tIT95sK31J5/rWmG1m59ETLRW7jociLewwz/MfqaheQpeW+P7+PzBFWWPAFU8b9Rtx2DEn8AamLbqR9Q6Mty/8f5J6CMfzNEnU0wnN5P8A7JA/8dB/rT2Hyk06zvKQo7IzU51S3/3/AOhrQuh5l7EnaNd5+p4H8jVO1XdqkX+zlv0I/rVyBvMlnk7Fyo+g4/mCfxp0Xajbuxz+Iex59qgtGAurlz91EGf1/wAKlY8GqqH/AEO+bux8sfiAP606P8S/a4ntYs2YKWUQP3toz9aqRsW1WAdgT/6CavdIRVGyGdULHoqM38h/U1MdakUPoy3/AK28kY/dQBB/M/0/KnSojDaygj3ptlkwBj1cl/zOae/Srm7tsS7D7Ny0RUklo22knv6foRTBPLKSYQgQHALAndUdk+LmZT02q388/wBKdpwxaRf7oro9o3CNiLasjnhimbNza4f/AJ6R8n/GqUmlqwMkQEqn+JeHH1/yK1mNRWrf6VIB0ZQT9R/n9KqnVbfKxOKtcyVjnjYrFMJNvWOUcj8ev55p/nOBiaCRPdRvH6c/pW3NBHMAJEyR0PQj6HtVV7SWP/VsJF9G4b8+hrV0oS8iLyXmZ8ckUqlYJVLDqAeR9fSnSbljVzyyHJx6d/0pZ4La4YJdQr5g6Bxhh9D/AIUi6cqH5HkZf7rSuPywf6Gs3hpJ3iwVRbSHIu+6kiQj99H5i/76kc/iCB+FJKeFmAIK5DA+nf8AL+lWLJILIny7V1JGN28yHHpknOPai4MJcyxSCNj95ZAVDe+exrSUHazD0K3kouXQDkdRUURYqyZ5NKrtGSI0Lx/3UIbH0wentU8IeQ/u7aYH/aXb/OubladixlrB5eS33q0dOTKPMRy5wp/2R/nNMSzdz+/YBP7i9/qavAAAADAHatqcGtWJsWiiitRAKWkFLTEFKKSl7UCFHWlpB1paYC0UUUCFFKKQUopiHCnCminCmhCilpBS0xBSikpRTAKKKKBBRRRQAUUUUAFFFYPjPXZNE0tPsMIutXvJBbafak482ZgSM+iKAXY9lUmgDH8UO3inXx4UtmP9mwKs+tyDo0Z5jtQfWTq3pGMfxiu1RVRFVFCqowABgAVj+EtCTw/oyWhma6u5Gae7unGGuJ25eQ/U8AdgABwBWzQByHiLSvsLPe2y/wCisSZkA/1ZP8Q/2fX069M1iI72kqywOU2/dcc7fYjuv+fp6URkEEZFchreiPZu09hGXtTy8KjJj91Hdfbt29uapTcXzRO2hXXwTLNvqC6jZSJgJdR4d4vXBByvqDipjOrRBlPGOK5Nfl2SwMSo+ZGQ8p7qf6f/AKq19Ovba5dVviI2Y4DqcRyn3H8J9u/6VzVabraxeptKlyarY0U3LYk9HuXwPZf/ANQJ/GrIUIgUDFN1I7Jbc9F+Yfjxj+RoeQbN2e1Y1/cfKuiMY66lO5Blu4IR0Zxn6Dk/oDWhendLCg7EufywP5/pVPTFMt88x+7GMfif/rfzqzCfOZpj0f7v+72/x/GnS92j5yCWsvQHO0ZqvZAvqAbsqk/yFWXAINQ6Wf8AS5x/sr/M1NFfvUOXwsdGd13dHtvA/JRUspwuKr2ZyJW65lc/huOKdcsQhxU1Hq2CRXs2KPd3A5MabVHqT2/lV2GPy4UXPQYzVSxTNpHn/lpMWPvj/wCuBV9+wq2rQivL8xN6sikOENVR/wAg8Af8tJ/5HP8A7LU90cRGokH+hWQ/vMX/AEP+NFP7T8hvoTyvhMCqlquI72T+8BED6E//AKxVx1AQmoYR/wASsHuZhn/v5j+Qp0V71+yE9i0nyAAdAMUNyDS4prnAotoBVjO2a5b+5CT/AD/wq5bLtgQegAqpCuUvW7FAn44P+NXU4WtUvdiSxG6GoLTi8YH+JOPwP/1xU7dOKgX5LuA/3mKn8if6CnDSSYdB8UYn3SSZJLEDnoAcDFODGB1BYtETj5jkqe3PpS2fCOvdXYfrTpkDqVYZBGDWt2tSQumUIqvF5odtu3j0J7/Sq8cELkiJ5Yn7oT0/A5/Spo/30DROf3i8Enr7NTQBPHhxiRTg4OCp9q05mtUKyejGG3uV+68Ug98r/jTT56/egfHqpBH88/pViGRg3lSnLfwt/eH+NWKtTZDgjKeSI/62NgPV4iB+ZFNVrTPytCD/ALLAVr0hAIwQCPenzC5Oxnqqn7rv+Eh/xp4Vh0lk/wC+s1YNvATkwx5/3RSmCH/nkn5UXXYfK+5Cu/8A56v+n+FO+f8A56v+S/4U42sP/PMfhxSfZYf7rD6Of8aVws+4gEn/AD2k/Jf8KXEn/PaT8l/wpRaxf9NB/wBtG/xpfsqf3pf+/jf40AJtf/ntJ+S/4UoWT/ntJ+S/4UfZU/vy/wDfw0v2Vf78v/fZoAAr/wDPZ/yX/CpFVu8jH8B/hTBbL/fl/wC+zTxAq/xSfi5pgSLnuSfrTqRQAO/40tAhRSikFKKYhwpwpopwpoQopaQUtMQUtAopiCiiigAqhrWtaXoVot1repWWm2zOI1mvJ0hQsQSFDMQM4BOPY1frzb46eHtZ8Q6N4bXw/a3NxcWGvWt/L9mkhSWOKMPudPOIQsCRgNkZxkYzQB3mj6tputWYu9G1Cz1C0LFRNaTLKhI6jcpIzT01KxfU5NOS8tm1COMTPaiVTKqE4DFM5Ck8ZxivBPHF54mk8W+GNIQ+MJri707UD9jbUbazuJZFAMbs1tIkOFOD1zgHIOcG1e+HPiyNHvo4dQuX1E+Gra2jlW+UK14J8y7QWGJTFlfMIGT/ABd6APZtL8Q6XqmsatpdhdebfaU8aXkXlsvlF13KMkANkc8E0n9hW7eJ/wC3JpJprpLb7LAjkbLdS25ygxwXwm4nPCKBgV4QPBHj61l8WXXhy11LTI9R1LT5hHd6is15cW0cTrKnmrcbt24r/wAtUJHAcVpaV4J8fX+p+HbTVdf8WWmjxfazeXCXsVvOudrQowWecuM7gGLM2ODjqQD3uqralYrqi6a15bDUWiM62plXzTGDguEznbnjOMZrxHTPCHj99W0yTUbvXRbSaxqAvgutsALFl/cYCy8c5xt+ZfbiotA8P/E9dI0xNYudcjuF8PXVpcPb30M0ou2uT5TbXlCO4ix85YccbgaAPfaK8++Dmn+JdO0nUIvFcFxHJ54FvJc30txNNGFA3urTzrGSc8I+PYV6DQBzus+H/Nke504hJWO54T9yQ+o/ut+h7+tcs8Z8yRChinHEkUg/mP616XVHVNLttRVfPUrIv3JU4Zfx9PY8VhOjfWOjOqjiXDSWxxlpqEluhtplMtv/AAxs3zL/ALjf0P6DitWzzeoRbTo4HBD8On+8v+c1m6pp1zpuftaiW27XCL8o/wB4fw/Xp79qpBXR0lgc7l+6wOGH0b+hrmnGMnaojr5YzXNBnZPAINOliiyTsbnuTjrSROpX5ehHGKxLHxBLG+y9Qyr/AHlGHH1Xo31H5VehmR0L2LieAdk+9H7Fev8AWitG6Th0MOSUNJF09DVfTSPtlyTwAoz+ZqKS8G3bg7v7uOfy61JbwSRafdyyArJIhIHcAA4rCgm6idtgltYk05f9FjJHJGfzpLzAjJqaAqIxg8Yqtft+6KryzcAe/as5bAtx1qMR2S/9Mi/4nH+NWZDimbNlxGg6JEAPz/8ArVIw7Gtqq1aJRRu8tGx7AU9hgWCekZP6D/Glv/ltpMehp7r/AKci9kiH6n/61KCtGXyHfYdJnBqGD/kHqP8Apvj/AMfzVmUVWiGLVh6XA/mP8aqmrN+gnsXccUyQcVKR8tNYcU+UVyqgxazn+9KB/wCgirgGAKqj/j0uB2jfd+WGq2OVFa20XoISq1wMNGR2kX9SB/WrQFQXI+XPoQfyOaLAh3+rvGHaQbh9Rwf6VMRmorv5UWT/AJ5nJ+nQ/wCP4VKORWklqSV5v3UizDoOH/3f/rdfzp9x+7YTjpjD/T1/CnuAVIPINNszutVVucZQ574JFOPYCOfl4gPvbxj+v6Zq3UENuI2B3M2Bhd38IqanFWBsWiiiqEFFFFABRRRQAClpBS0xBTh0ptOFAgHWlpBS0wFooooEKKUUgpRTEOFOpopaYmOFLSClpiFFFAopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigA69awtS8OW85aSyb7LMeyjMbfVe34YrdoqZRUlZlRm4u8WefX1jdWSt9utiI1/5ar88f1z2/ECqgj5EkEnOPlYMc49mHNemVj3/h6xumaSNWtZjyXgIXJ9SvQ/XGawlQa1gzrhi+k0c3a63fWwAmAnjH9/g/8AfQ/qPxrXttfsZowZWaDPH7wfL/30Mj9apXOgahbqxi8q6UdNp2MfwPH61jzKsUu25jkt5T/z0UoT+Pf9ajmnD4ka8tKrsdQlrvQNZXKNCfu/xAfQjtU9tY+XIJJn8yQdOMAf/XrjlhaNzJC5VzyWUlGP/AlxV2HVtSt+PM81fSRA36jB/PNRFUr81tQlRl0Z013mOVJsfIFKt7e/060vmI2CCCDWND4lwB59rhv9iT+jAVINR0uY5YzWrH/ZIH6ZWnUp8+sWZeznHdFy4PmSRxryWYDHt3/TNTMP9PkP+yv9aj082RffBdJO+MA71JA+gqe6hcyCWLBYDaVzjI7UlSag+5LeorYqtGMwXGO06n8BsJpwM7fKIHB9WIA/nVmCAJAUfDF8l/Q5/wA4opwd22gbsKCMUjHioDFNCMKPOUdOcNikMkh+UQybvQjA/PpQ4yWjQtAUf6HeN2bdj8FA/pVmH/Vr9KWGPZAI2weDu9yetQKZLdQjIzqOA6jOfqOtauLSQtyzUFywwF6liFx9aaZmb7kUpP8AukfzqSGFvM82XG4cKo6L/wDXpJNhsTkAggjIPBFVYXEP7mRgGXhcn7y9j/jS3V/a2v8Ax8XEaN/dLcn8OtZV34htvux27SjsZfkB/A8/pVysOMJS2RqNOHysX7xvReQPqe1VrrUrXTYfKdxLOoyY065Pc+g+tYFxqV/dqVD+RDjhIhsH4n735YqmsccbIuC7sfljRckn2Udaz51HY3jQ/mZPd3VzqMhecgR9k52AfTv9TTLd7mycPaybcfwqMKfqvQ/oa2dP8P3V1te9Y2sP/PNcGRvqei/qfpVm98MFPm02cgd4Z2LD8G6j8c/hRyVH7xXt6S9zoNsPENvKCt4Ps8i9WJyn59vxxWyjK6BkYMp5BByDXEXcL28gS+ge3fOFZuAfow4/WmQCe1ctaTvFk5O04z7kfdP4ihVbaSE6EZawZ3lFcrb+ILyE4uoY5V/vAFD+mQfyFXoPEdrJ/rIpk/2gA4/8dJP6VopJ7GLozXQ3KKoRavp8pwt3ED6O20/kauI6uMoysPUHNUZtNbjxS0gpaZJnahqTQXC2lnbm6vWXf5YbaqL03M3YdcdSaLXVPMs7qS4gaK4tAfOhB3EYGRg9wR0NReHkDHULtuZZ7qQEnsqHYo+mF/U1V1i7XS9aSUwvP9ttzEIYxlpHU5Ufkzcn0piLaaskf2qWckwL5UkeByI3AAJ9t26seHxa9/cWklhEotVXfdrJ99QZAgx9M7vpWdp4up/KsL22WGFon0mUtLubIUtGcAf3T696qeH9IkiuYAVKrqFhNp0xx9yaPK5P1Vf0piO9e9MMlz501sI4P3snJ3JFtPJHrkH8Kw9cv5YPEFpdRXMgtEhjfywfkkV5CrnHcgNGay1v7ma6vpn065nglslsrpY0JYTgNxjuOcZ9xTLu01K/0bTtKubCSDUbQKpumcLCYwBn5u+4ADGOCM0AXtHv30ptTeQvKxt5bpkZj/rY3ZXHsCDHV7UfE8lr4UbVRAqzRTLFNETuCkSBWAPfjOPqKxW8xNZvb+WKyMdzC8DWZvASCwUO/wAqng7AMdeM98VHpcL2lrb2d9cLc2cU/wBpbZEyvK+cgFnIGAcfXApXQ1CT2R6LDIk0SSxMGjdQysOhB6GpRXnkUup28ItdMvZIrBciNDGGkjX+6H5GB2yM+9asF7qQt44ll8tUUKG6ufqzbsn3pe0ii/YTe514phuId20SKW9FOT+lcqsc0x/0md5B6Ekj8icfpWrYrEmFByR2zn9KaqX2FKly7s2lIIyKWmRfd9PrT60MAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApksSTIUlRXQ9VYZBp9FAGNN4b06Rt0Ub25/6YuVH/fPT9KzrjwxcoSbW8SReyTpg/8AfS//ABNdVRWbpQe6NY1px2Zwk+lalBnzbFpF7tC4cfkcH9KzZvIgb/SEa2b/AKao0WfzxXptBGRg9KzeHXRm0cXJbo8z8mKZchg47Hhv1NKkc8X+ouZIx/ssw/kcfpXfS6Vp8pJeytiT1PljP51Sk8Naa+dkcsR/6ZzMP0zipdGa2ZqsXF/Ejl47/UoxgXLEepYH+ampF1fU1PDhv96NT/IituTwrF/yyvrpfZtjf+y1A/he4H+r1BD/AL8H+DUuSqh+2ovdfgZ669qI+8tv+ELf/FmnDxDed4oSf+ub1Zbw1qA+7dWjfWNl/qaZ/wAI5qn/AD0sv++m/wAKLVewc9B/0yE+IbwjiKEH/rm5pja7qR+4sGP+uJ/q9W18N6kT809mv0DH/CpU8MXZ+/fwL/uwE/zai1V9A56C/pmWdV1Rv+W2322qo/karSveT58+6lIP8O84/QgfpXSR+FV/5bX9w3siqo/UGrUPhrTUILxyzH/ppKxH5Zx+lHs6j3YvrFKOy/A4pkgtwN8ixg+4XP5YzVyzsrq45srGZgf43Xy1+uWwT+Ga7q2sbS2bdbW0MTYxlEAP51Zqlh7/ABMiWMb2Ry1n4Zmchr+6Cj/nlbj+bnr+AFbun6ZaaeD9lhVGP3nPLN9WPJq5RW0acY7I5p1ZT3YUUUVZmNkjSVGSVFdG4KsMg1jXHhqwfJg821J7RN8v/fJyPyrbopOKluiozlHZnH3HhzUIiTBLb3K+jZjb+oJ/Ksy4sbuIn7TptyP9pY/N/wDQM16HRWLw8XsbxxU1vqeYGS2DbGm2N/cdsH8mpfssZO+PaD1yFH9MV6ZJGki7ZEV1PZhkVUfSdOfO6xtee4iUf0qfYS6M1WM7o4NftKfcupV+kjj/ANmqZLzUFHy3Uh+smf5g11snh3SnOfsgX/cdl/kaibwxpp6C4X6XD/40vZVF1H9apvdfkcSp1yCeU2GprDFK5kZJI1kwx6lTgYz1wc1FPFqMN9aX6TS3N4s6h5HZSQjAqcDbgAZzgeldyfC9l/DNdr9Jc/zFN/4Re2/5+73/AL7X/wCJp8lTuL21Lt+BzuLlrkzswMpkEuSw4YLtyPl644qZXvACFnZAxLHa+Mk9TworfHhq173F4f8AtoB/IU9fDdgOpum+tw/9DRyVO4vb0+i/A5wxXD/fupW+ruf/AGamGzgXLylT7sq/1FdZHoOmoc/Zt3++7N/M1Oul2CkFbK2BHfyhn+VP2UurF9ZS2RxSS2eSscwkYfwRtuP/AHytW4LeVzm2025Y+pi8v/0PbXaqoVQqgADoBS0/Y92Q8S3sjlo9K1KTkx28AP8AfkLMPwAx+tXoNCYc3N4zH0iQIP1yf1rboq1SijN1psoRaRZxnJRpD/00Yt+nSrqIsa7UUKPQDFOoq0ktjNtvcKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal nail anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The nail has several distinct anatomic areas. The hard nail plate emerges from a matrix of specialized epithelial cells. The matrix begins 7 to 8 mm under the proximal fold, and its distal end is the white crescent called the lunula. The richly vascularized nail bed lies directly beneath the plate to provide adherence and support and is the basis of the characteristic pink color. The proximal and lateral nail folds surround the plate on three sides, and the cuticle, an outgrowth of the proximal fold, provides a seal between the fold and the nail plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, AB, Wolff, K, Suurmond, D. Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 4th edition. McGraw-Hill, New York 2001. Copyright &copy; 2001 The McGraw-Hill Companies.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Diagram of the nail biopsy techniques",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33738=[""].join("\n");
var outline_f32_60_33738=null;
var title_f32_60_33739="NNRTIs PI";
var content_f32_60_33739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Non-nucleoside reverse transcriptase inhibitors (NNRTIs)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing instructions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects &amp; interactions",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Efavirenz (Sustiva&reg;)",
"       </td>",
"       <td>",
"        Take first dose on weekend (to ensure tolerable when not working), usually recommended once per day at bedtime. Should be taken on an empty stomach (one hour before or two hours after eating).",
"       </td>",
"       <td>",
"        May need to avoid driving or work for first few days due to dizziness or \"hung over\" feeling. May cause depression, anxiety, nightmares, or vivid dreams. Must avoid pregnancy. Interacts with many medications. Avoid St. John's wort. May cause depression that responds well to a medication change, but it takes weeks for the full effects to wear off.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Nevirapine (Viramune&reg;)",
"       </td>",
"       <td>",
"        Usually taken once per day for first 14 days, then twice daily. Take with or without food.",
"       </td>",
"       <td>",
"        Skin rash is most common side effect. Can cause liver problems, especially during the first 12 weeks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rilpivirine (Edurant&reg;)",
"       </td>",
"       <td>",
"        Take one tablet daily with a meal. Must avoid concurrent use of drugs that reduce stomach acid.",
"       </td>",
"       <td>",
"        May cause depression, but this is less common and less severe compared with efavirenz (Sustiva&reg;, Atripla&reg;).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The information contained in this table is a supplement to the standard educational brochures your pharmacy provides. The information in these tables highlights a few issues, but is not all-inclusive. Read the complete information provided to you by your pharmacy and/or healthcare provider.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33739=[""].join("\n");
var outline_f32_60_33739=null;
var title_f32_60_33740="Genetic basis of SQTS";
var content_f32_60_33740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic basis of SQTS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        QTc (msec)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Locus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene (cardiac ion channel)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         SQT 1",
"        </strong>",
"       </td>",
"       <td>",
"        286 &plusmn; 6",
"       </td>",
"       <td>",
"        11p15",
"       </td>",
"       <td>",
"        <em>",
"         KCNH2",
"        </em>",
"        (I",
"        <sub>",
"         Kr",
"        </sub>",
"        ) &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         SQT 2",
"        </strong>",
"       </td>",
"       <td>",
"        302",
"       </td>",
"       <td>",
"        7q35",
"       </td>",
"       <td>",
"        <em>",
"         KCNQ1",
"        </em>",
"        (I",
"        <sub>",
"         Ks",
"        </sub>",
"        ) &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         SQT 3",
"        </strong>",
"       </td>",
"       <td>",
"        315-330",
"       </td>",
"       <td>",
"        17q23",
"       </td>",
"       <td>",
"        <em>",
"         KCNJ2",
"        </em>",
"        (I",
"        <sub>",
"         K1",
"        </sub>",
"        ) &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         SQT 4",
"        </strong>",
"       </td>",
"       <td>",
"        331-370",
"       </td>",
"       <td>",
"        <em>",
"         10p12",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         CACNB2b",
"        </em>",
"        (I",
"        <sub>",
"         Ca",
"        </sub>",
"        ) &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         SQT 5",
"        </strong>",
"       </td>",
"       <td>",
"        346-360",
"       </td>",
"       <td>",
"        <em>",
"         12p13",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         CACNA1C",
"        </em>",
"        (I",
"        <sub>",
"         Ca",
"        </sub>",
"        ) &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         SQT 6",
"        </strong>",
"       </td>",
"       <td>",
"        330",
"       </td>",
"       <td>",
"        <em>",
"         7q21-22",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         CACNA2D1",
"        </em>",
"        (I",
"        <sub>",
"         Ca",
"        </sub>",
"        ) &darr;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109:30.",
"       </li>",
"       <li>",
"        Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442.",
"       </li>",
"       <li>",
"        Templin C, Ghadri JR, Rougier JS, et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J 2011; 32:1077.",
"       </li>",
"       <li>",
"        Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005; 96:800.",
"       </li>",
"       <li>",
"        Bellocq C, Van Ginneken AC, Bezzina C, et al. A molecular and pathophysiological substrate for the short QT interval syndrome. Biophysical Journal 2004; 86:60a.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33740=[""].join("\n");
var outline_f32_60_33740=null;
var title_f32_60_33741="Time course cardiac ischemia";
var content_f32_60_33741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manifestations of myocardial ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 269px; background-image: url(data:image/gif;base64,R0lGODlhrgENAcQAAP///4CAgAAAAEBAQMDAwFBQUBAQEHBwcKCgoCAgINDQ0DAwMLCwsPDw8GBgYODg4JCQkJ+fnw8PD7+/v+/v729vb8/Pzx8fH19fXz8/P39/fy8vL4+Pj6+vr9/f309PTyH5BAAAAAAALAAAAACuAQ0BAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqMEBKOnqEABAamtrjerr7KzLrG0t7gktrm8s7u9wKm/wcShw8XInMfJzJfLzdCSz9HUjdPV2IjX2dyD293gft/h5Hnj5eh05+nsb+vt8Grv8fRl8/X4YPf5/Fv7/QCt/AtIMMrAggiZHEzI8MjChhBZDGAF4EABGA8jaizxIECCiQEWDMBIcaPJGwQE/6hcWbJFxpMaGxBY4KCUghgvYWpkwKrjzRc5dUJMQHHARaAthSptIcAUgAAjkS6d2iKBgwYNaJKkyjVFgJVNt3YdWwKBUQY4k5LlqqCUTbFrxw4AG7WW2rhLEaz6CgEuXrIDHPj9u7QtAQYG6rq8S9iESoZzWQ5ufOJxQr2rEKSlvMJy3KAwPQcEu1IxC9AmLQhIgHDAAAMiXwuWyhnFBAGmAxpwemC23dq2cTMUILhBgdwqUG+MIOAowgNgGaNQrlGDAOn8ILjuOxk4gAoCuH/GTjlD2ITGBRg4sNl7iQsCfrbGveB6d+CiCwpAWxG5V/KE3bZAQwawYpxzi7knAv94Kg3IEHQr8febexVIEMEEEUjAnggyOfWCAgNoho12BUg4oXcCRDACcyNAaCILHXkYDQIiykBdQgJYMMJtIySg0mwEBMCAAwPwp0ABBazyQIxPIaDdVQAQcNwA4uFyHA03IpTiigKIwEB4BgjQwFPqRbakAQXOVYp9DfooWAAOQCVAjbcgkIBb8iVIoYUYaiiCAwI8AKhmX5kCXZBzkrkmK8I10CgEBdQH4CmRqeTfdJOuxaAAGzqKm48DFqqoqIWmxGhUwi1gAAQQ2JcLZpnd1xgFKo0pQqtxBhCmAqQ29WUBBKhpKgDCETvSagRAl+koMuV5oncdCOCgCPXZCt3/Ab0aql59ixorgnAIWOoqLuE2aOuzwGHAKQ0QHFZtNwYQBZ1veronQXw0+Cjti9XsJsIBl56QZUGqsRZRAAeU4gCwzv6nIHgbQlRpaehydm/DCMG6F53JLctVtAZTNnBA6kbc2Mj90BpobSjzw4G0wLWcD3wcN6QAtwlUeZrHSm1K7wNuyZjCACbLADALvAaAAFZBl3KuJKrudjRtjVV4YYYRf7USUwGzoNcKgIqEW0qkCa2EqGLsN0CQXZcgczxbisDiCClF1QDAE4mAwHEHOEplYLaaRaUISkOFwJEFjPk1AA8AXCLdMAPQAAQdquQ0CdoR/QAAgnPXAJGrmKIX/wNEfz7AT1KWzrmQSCrwwFwO1MzFqkVaJetYOe7YJeRRJVDgAax9leSdbRJXEacFhEestGEmUJ9gc0mOJpx1PdDgASbmBwCg2C6QLPLK19ebfXMl4GNiqwHwK3QXlV9fAgqAWnQXWlt+e1dxAzC3CHWLgGacm4sXh/wmOeHEaxXCEY6ohBO9VolocyNggL6M963dkSB5STLFAb+yNuMNK3of7FLyVuEjAEQPAPVRFBlIxK8VvA0eH+AT1kjQPwAc6XzWU0yxEkiUWCkwLAzsEtpIYKsHlGsE2vtcffazmo0NK4RRIl+X5rIXVpwwekMEA42wxDOYUOBeKzHZA1rlPf8TIiBY8Uleu4C1w5GMkABf+6EpgmhDacHROQTIGQFaVRftOaBd0IHUdeAYAEfdSVkm7BIUWwWsISVSBFgcpBiuNIMXssM6/qmfCFWSAM18rnk5/NZIPqmeU6mQjupbYkkeUIAwGQBKFTSBrtTDHlIWiHNhouIjofgUfbVvd9F7gI8Q5AU74el+U/GA/fhwRint5w8Ta5suumgSdUkzDoBqIiA0JjuH/UWZ59GJYd5CtbiYh14wiSYyhXKblSkFVsorJ1ngQ83WoNOF9WyIdQzwNHGWAjHXJFw+EbIpYtLNLUTUCwQe0CwRtEUEQIMgCkDUzRiYBWOVmJjHLMkNq/X/aX7LU4kBbqKAMK3EUyLw0U3m0kLI5fOEQZJoJmBVUUyRJX/7I8FjGAkAH/WlcShsivWUVysiQuVxw2rAUdHCk83pRSZT6kseBxlTGxKpb4wTEsAGmgcF3AQCNRUYV0ejIxHwyDGKxI0CIjcCvpCRjaZRVUjiMyy51kcB4eqLAOEkJxrlUi9ChY2uBkS21ySqEQvAlkpaalPcqUhuFtTpdepzxmJBDklEW9W46jgRQAXAVGvt7HUaAJu1GghSknqkolqFFui0xT5fGqsdmjKABSBpnRqJlgz9hFbXaMZ6/ISo/3wkpNXgi3d7WVTdkrs94qxMVaySIuGakq0nblYR/0zEVkCfItt8fFFaYURBfgBFFAcYQATJw5dITYCmM4J1WO3do2a+tMNDSpEBvGrKWoHluyiyYliNSO/eDNqxrnyArSrIz91cOZtWnRcAGDTBkTjJgGFNeDX88ZGIyqVLxIRHVHaS1k2s2106sLJvRcJtQ1523LF4FQBgbc9SVBNPsiRWa4wV61QosIHm4IW2tiWwN5WiruDGJbtQUXFBWGy2rgj4tvJMjUp0RpYTNyDFUdbId4U8lqYGAKONPYnPUNAAzJA0RC+YGulChOYnrBnMI6CoDaYmMNd8AUJSumeBxbzb+ZU0MT4iAJNc8DXrLeCzn63BCW1g6ADIFAWDpv/BosvSnElNmgmv9F6Ss9wQnEYWks9Un+sSbbrQNelJimMFoEI06L2VLnWD6wgDthol4spIadqhiFLPEqUvn3HVCGASkxhwnJoMmoWEcxLgSkC6ApQwSnxrwOuIY4rUYXVy25lqoptAWwIQScn5YE5ZAXBWEgDKAAVYqH+DOj5GSctNj3xfwuwjPI8EKU5zqSxuwuRX3NCJlmpEYYHu+pUwzTUB8/7vdcKVpAza51rJQ0vx6PWlQ5dwfc2Jn7QQgPFfHuAABkDAX51Q2wQEnNMIofFj9fdpyWVTPa/9rAfZNEo6khgAApQcVlA7SNhKtwSNUitu4HSdr/Dn5qYio9L/1g2bAl4k6IpJ3uaiN0KPCDEsVVcpBafeciWU1FzgpocF7mWAPpvAVmiUudrX3cZd2mdYlhV4dNfOS52iqoMgQfR5kE7vyCTcW95q+wiuOMWix0JUVEzuZi/dBALAOcwN+e4C7hZeEwSmwtwylSG/Z0pvgfDt9lGjlFJiX7rfN092BJReQy5ftFm4lFSEQMIYPqyI8wXwcf+KkErIyMO8KSy9dySaGMCAAbH08UOwcyVLzA0eS6ufKIDAEheAlmGJHDc0F6XbFW4g867GiOIyPSs8XCX1hGlDF04AT/buKuhY5ToSVEnikpq89Wgf8Bwq37Ot7mO08f8iFzYS5OcE/5tmI8yHDc5nAI9GA80UcU8Qd6MAHa5BNGGXDgmIfC6QTUQBBRAoCuqEcvzQYyOlIDjAUbdQZBiIF3fDaxVIDurSYiQ4MTkmSwfYDC8YVpRhH1mxXSboChRgHodFgiPwOE/BZToGEM4HFocGfR1SCjFAgYoGUktwNBd1AlV4AlCINMeBg0jTZkjgAB8xAOaThfgEEGN3ARowAWo4ARpwASNIQ2ChgEDBhSnQgUwAQo4mMOEEdNfkO9tmI2ERaUcwMZZSMfHwRRiAAhjwYLzTXBRhbWNSaom2dOpzHNwxOq3DOESiOhA4OqVDJF9FEQHQFyvoAD+BbYODN6bYa3hlCv/NVkJVpYo3kUVPERi4oVS/JSSVGBhwpE2UuHSYWAA/4WoHACLEEWykBjCreGrLZhA1CAwWAB8TEBwl0D/JM1/NwT7s5lnegnHs4T7pEyxEJxgQqH9lkj6A4lXGY1dyOBcfd17yslfqAX/SYnUqFI/Bs4fsw0E9dV4OxHABkCTQkRi4NxLgmI/DAwHyU1cDJ4cT1wMgsnz5MHYqkYgnsIjVCBazkXVNMXOmlDxjoiqqlUKcQyQJZBqfZ0Vp9XHxsVbs8SUQsFazsTnJYlhkwh9S90iiUpNhokIjkHM/VHz+WI8iIniolEI5hxU7eR0uqT5EVXPb1QIpIZH1kCF2ZAD/aLiGbOiGzpISYnMUiRc6oGdKhKda0XMt/VOOaaWSKRUvhDWWAOaUJZJCaFOWhfIrxXd1MtJ2hrYutagS7GGUBglMXZJ7YWEqNyd4OzCVBliVlhKJc7USS2gCdUNayhN8V4EsiCQcrVJcvwRqicQA4XIsKLmWqqU13BEvznQTw1d8uhd/PvmaJVQosqmXJMBSowlq+CJ7vfh0UXF+q2aWm7RGiPJZ8HUnyXMTiqkDjClj7fCCesYC/fMlI/h/uIR9nQdyzTEmZfl1c0GaJZCSqjVUtnIzqyEiAZgVqzGb53Fl66mX6mk+thlnPvKdehM58bedgCdy64FK0UNKCbAk/8NkYe9TlHcnBT3YCT+oEs9IAg0YaknwJdE5BdBBh2RgnnlEZXuWDhYgghZaAxrYoCyQPE1GBWgCfWwQNTXZgsQwAWSXgkL4LaTDNiwKDCw2eTEKA7QjQRN6hOFAAQdWeTnqEmBRopDHDR0qAGY3pC2AbDV6C1bpaUzqNU5BfE8qCxTwgnMxbuU2pSiQN/1xpa6QpGyycjnlpXBIGkZIg9nAAWTHG0uKpiUAIvHiGsIopqcApI9JAhDil/wTNCtYA3LWBWQoCmfERdTQAWC0LGXDeC8QlygAqQpBKHvoCZOzMXgKChTAIAsAo8vjFu7pUFc1JqOYVa6Yh/zDKbSmif+BcROrZiBLZaqiaVWqoz6BYQuQuDrEdqecsx3JNm2xwyvV9mWakF6FCIK5MAHwwSkommCG90gPIFhNB5IMJ3BpaljBJq3n9T4jYVd0NY8DEK2H1nQVZ48dl0jOkz4Q95Qal1jWcxE5mQmcQlsbJaKWsKmcZKTOujUN9EyuFS7EVi0UlKrjdx24IifdElpEJ3MbwlrHY4xcB2FFV0InhJQ9dJI+ORfvuglNoYAFWC/BoKyA2awsIBqRZAqFYj0V6lwmQmJfkSuOZl151y0qVChlGZZs+UhN5EMjgTbhUh8zCAkh52wEiayvkKX5agMm2yX7lUcPVh/nFRlPQ2JrRX3/yfJajxNf7+UqTdtfygKbmCmcEvtZcdSzkmSZjDhTh4MmnpqghRClWKW0kXVCIdapt+JjPAWH3JdKDcJ155V+FTYudXsT7imfhONLYmtLpiRMPtZcUpgJbWuvj+ABQFhGemBEcNR0PlAfC1gJQcIbPCi5jEAB1lFKffB1GecDobUJa8Wg9RG6uNAByxqucvoDuhKZdmu0oGABQKh+tasKI5ESjztkrYC0pUSyvwsLifG6hVqGxasBYFQAnZu8OqBJx2qIoBABs6uv1IsDQNM0kYsKsstJH9q9S+C2dDABQHhL5usPotsH6itShdS+XIC+bxC/P4K89DsF9ssG+Esc/9O7vwLxvnbQAUAIwAL8Bf17BtorUg4QwAl8BQs8BqS7rAWivxE8wJTgARgARjmDwRmswZFgwJJZviHMvwScBhTAAcvaHNx7wlowwVkwAS9ISxAMw/WbwmPgASxcGiaMwyJsCBEQpOqxjEB8BjIMBTQMRv52xGuQxExgARXQwkRxw04cBlCMBFLcwq/kqVfsBVlMBB0wxSvxSkH7xWQQxj9AARHQwWXsAGeMxvagw01gARpwwKuBPXKsDnSMBB7Qxkxcj168x3PcBn+MAS1cxEtDyHigxi8wARzwAYmMGzHJyHvgyClgARFQAXhsKX9oyZcsuZtSATcAyZxMGquRbv+DDMruYK8elSGk7AIeYMoZMMllIiQgzMp3kCVSagIWMAEdoAGc3GOoLC0ZlMu6rAe8zKUCIMwZkAHEXMxlEif4lczW0F2egspmKs1hGDovbM2HkBPFnAC7lSTG+c3g7AgD06fDm86WgMnuvAjwHM+JMM/0HM4HCKj3LAqgQRpxTIv7rAj93CW5CW2qs4ITAaw/HNDKfIA7ZTzn6ofA067tzNCBMNBgx5E490p5CNAWbQgD7X7caXiscEPq0RGV+tEg7dCFdxFhGyJolF+frNKFMNCMw2+9JH8Se56MM0w0rQ19/NPSENRCDQn2XNShjNTNcNRK3chE3dTy/NRQXc//Uj3V+GzVxMDUWC0HWr3VcNDVXu0GYB3WbDDWZC0PVX3WfwAVVdTWbv3WcB3Xcj3XdF3Xdn3XeJ3Xer3XfN3Xfv3XgB3Ygo3X6EwFQTLYiJ3Yir3YjN3Yjv3YkB3ZcV3Yal3Zln3ZmJ3Zmr3ZnN3Znv3ZosATukgEgwrac6CetZV9PCAqgmjaX+2XCiCaTQQ0vlZt0UarBaAZCkAkuT0CCs0kQbKru/ZARGLErv0FHEasA3k6BUePBcA+jbYw0e0cFD0sBQe1qhIo4qoraXvcYGxSiVIsRodeExsfeUw5a4VwlKMLh0lvQGS2e0QcCOvdX1CeEgh4dUnSthomA0I6gPzN3tXm3nME3y+7F1ZM3wgK09yILCjtFJjpbRWGJhBOAGjC3sYp4N5SKFVbYcWI4F2ARtpEJvExRP/3ANPnOidOAozLRqywQPDNt9Jy4B4+4zRe4zZ+4zie4zq+4zze4z7+40Ae5EI+5ERe5EZ+5Eie5Eq+5Eze5E7+5FA+CCEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the relative development of the manifestations of myocardial ischemia as the rate-pressure product is increased. Regional myocardial dysfunction, which can be detected as regional wall motion abnormalities on echocardiography, occurs before ECG changes or anginal chest pain.",
"    <br>",
"     <br>",
"      PCW: pulmonary capillary wedge pressure",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Modified from: Beller GA. Am J Cardiol 1988; 61:22F.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33741=[""].join("\n");
var outline_f32_60_33741=null;
var title_f32_60_33742="Omphalitis I";
var content_f32_60_33742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Omphalitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Omphalitis. This photograph shows omphalitis, or infection of the umbilical cord stump, in an infant with leukocyte adhesion deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33742=[""].join("\n");
var outline_f32_60_33742=null;
var title_f32_60_33743="Thyroid calcification Echo";
var content_f32_60_33743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thyroid calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonogram of the right lobe of the thyroid gland in the longitudinal plane that shows a dense bright arc (arrow), which is a coarse calcification. Blockade of the ultrasound signal distally produces shadowing.",
"    <div class=\"footnotes\">",
"     L: thyroid lobe.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manfred Blum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_60_33743=[""].join("\n");
var outline_f32_60_33743=null;
